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Abstract
Purpose: To compare helical tomotherapy (HT) with mixed beam therapy (electron and IMRT) plans for
superficial parotid gland and nasal cavity tumors.
Methods: Mixed beam and HT dose plans were developed for five patients with superficial tumors
(planning target volume or PTV < 5.5 cm depth), three with parotid gland tumors and two with nasal
cavity tumors. Seven mixed beam plans included a 5 or 7-field photon IMRT plan optimized on top of a
single en-face 16 or 20 MeV electron beam dose distribution. The ratio of photon to electron beam
weights (at depth R100) were 1:0 (IMRT only), 2:1, 1:1, 1:2, 1:3, 1:4, and 0:1 (electrons only). Planning
objectives for HT plans were set as closely as possible to those in the mixed beam plans, and were
determined using our clinical planning protocol for head and neck cancers. The resulting dose distribution
from each plan was evaluated using dose-volume quantities, tumor control probability (TCP), normal
tissue complication probability (NTCP), and a clinical evaluation by a radiation oncologist.
Results: In general, the HT plans showed better target coverage and dose homogeneity index (DHI) than
the mixed beam plans. For the parotid patients, the DHI improved an average of 0.056 and 0.035 for the
nasal cavity patients compared to the mixed beam plan. TCP was comparable in all patients. NTCP for
the mixed beam plan was generally lower or comparable to HT with the largest improvements seen in the
contralateral parotid, eye, and lens. Also, the mixed beam plans yielded more favorable PTV and normal
tissue results for a single shallow uniform PTV using a heavier weighted electron to IMRT ratio (1:3 or
1:4 ratio of electron to IMRT).
Conclusions: The study showed that while HT plans had better target coverage and dose homogeneity,
the mixed beam plans (electron and IMRT) had comparable tumor control probability and have the
potential for improving NTCP for distal normal tissue for superficial uniform PTVs.
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Chapter 1
1.1

Introduction

Head and Neck Cancers Overview
Head and neck cancers comprise a large group of malignant tumors that account for roughly 6

percent of all malignancies in the United States. The annual incidence for head and neck cancers
according to the Surveillance, Epidemiology, and End Results (SEER) program is 25 per 100,000 in the
United States (www.cancer.org, 2009). Often head and neck cancers are treated with radiation therapy
either in conjunction with surgery or as the primary treatment. Over the last several decades, advances in
radiation therapy delivery technology have lead to new treatment techniques that have enabled clinics to
treat more patients definitively, better spare organs at risk, and generally improve the quality of life for
patients following treatment. This general progression of treatment techniques is now described.
1.1.1

Treatment Techniques
Superficial head and neck cancers have for many years been treated with electron beams, often

mixed with photons (Tapley, 1976; Vaeth, 1968). The electron and photon energies and the amount of
dose delivered by each were determined based on the maximum depth of the lesion to be treated. The
advantage of the electron beams is that the distal dose distribution rapidly falls off. Superficial planning
target volumes, PTVs, especially those with distal critical structures, take advantage of this fall off
(Hogstrom, 2003). Because electron beams have no exit dose (besides bremsstahlung) past the practical
range (Rp), they are particularly useful when treating unilateral targets, within 6 cm of the surface, that
require a low dose to contralateral tissues such as nose, parotid, ear, oral cavity, and oropharynx (Perez,
2004). The photon component of the mixed beam helps spare the skin at the surface and increases the
depth that can be treated. However, these treatments have limitations. They often treat large volumes of
normal tissue to high doses in order to obtain the desired dose to the irregularly shaped planning target
volume; this sometimes required to abut fields which lead to dose inhomogeneity. Also, irregular
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surfaces and internal heterogeneities can lead to increased dose heterogeneities, i.e. hot and cold spots
(Hogstrom, 2003). These conventional techniques have been further improved on by IMRT.
1.1.1.1

Intensity Modulated Radiation Therapy (X-rays)
Intensity modulated radiation therapy (IMRT) with x-rays is a type of radiation therapy that uses

computer-generated images to conform and match the radiation to the size and shape of a tumor. With
IMRT, the radiation beam is subdivided into small beamlets of radiation that enter the body from many
different angles and intersect the tumor in such a way that the total radiation dose can avoid normal
tissues and create concave shapes.
Over the years, intensity modulated delivery techniques have been shown to improve dose
distributions compared to electron and conventional mixed techniques. Intensity-modulated radiotherapy
(IMRT) in many cases can be substituted for a treatment in which external beam radiation is an
appropriate choice. Cozzi et al. (2001) found that IMRT was superior to conventional non-optimized
mixed beam treatments in target coverage and organs at risk (OAR) involvement in five advanced cancer
head and neck cases. The mean conformity index value (the ratio between treated volume at 90% dose
level and PTV) for the five advanced head and neck tumors were 1.93 for mixed beam and 1.60 for
IMRT. The IMRT provided an advantage over the conventional mixed beam plans through increased
target coverage and avoiding the spinal cord in their deeper advanced head and neck cancers.
The main difference between conventional static mixed beam treatments and IMRT is that the
latter provides an extra degree of freedom (the intensity modulation, usually through multi-leaf
collimators) and is able to conform well to PTVs that require steep dose gradients (Khan, 2003). Because
of the intensity modulation, highly conformal dose distributions can be delivered. This leads to plans in
which the dose to the PTV can be increased, while at the same time decreasing the maximum dose to the
surrounding healthy tissue (Ezzell et al., 2003; Galvin et al., 2004). In most cases the result is better
tumor control and lower normal tissue complication probabilities. The previous studies compared static
beam IMRT. Another means of delivering IMRT is helical tomotherapy.
2

1.1.1.2

Helical Tomotherapy
Helical tomotherapy is an advanced type of IMRT, first developed by TomoTherapy Inc.

(Madison, WI). The TomoTherapy Hi-Art System uses a technique where the patient is treated by a
rotating gantry with a linear accelerator head. The patient is translated through the 85 cm wide diameter
bore as seen in (Figure 1), much in the same manner as a helical CT machine. The Hi-Art system uses a 6
MV fan beam, collimated by a binary multi-leaf collimator, to deliver a helical intensity-modulated
radiation beam (Mackie et al., 1993). The binary multi-leaf collimator consists of 64 leaves which can be
opened to project beamlets at 51 distinct angles for each rotation. Therefore, in a single rotation around
the patient, the binary multi-leaf collimator is able to produce 3264 possible beamlets. When all the
leaves on the multi-leaf collimator are retracted, the maximum field width is 40 cm at the axis of rotation.
The theoretical advantage of helical tomotherapy is that the large number of potential beamlets will
improve the adjustability of the dose distribution.
While relatively new, TomoTherapy is a treatment modality that has come into use for the
treatment of numerous disease sites. Previous works have examined helical tomotherapy (HT) and
generally conclude that HT is capable of delivering dose distributions that are equivalent to or better than
distributions delivered with fixed-beam IMRT. Lee et al. (2008) found that HT significantly improved
target dose uniformity and target coverage for parotid tumors compared with fixed-beam IMRT. HT has
also been compared to mixed beam techniques, that is electron beams combined with photon beams, in
the chest wall (Ashenafi, 2006) and found HT to be an attractive alternative in post-mastectomy chest
wall with supraclavicular fields due to the maintaining a uniform dose distribution to the PTV while
sparing normal tissue (e. g. ipsilateral lung in this case). Also, HT has been shown suitable for disease
sites historically treated with electrons. For total scalp, Orton et al. (2005) showed that tomotherapy
plans had more homogeneous target dose and improved critical structure dose when compared to state-ofthe-art linac techniques. Target equivalent uniform dose (EUD) for the best tomotherapy plan was slightly
higher than for the conventional plan, while the volume of brain tissue receiving over 30 Gy was reduced
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by two thirds (Orton et al., 2005). For medulloblastoma, Penagaricano et al. (2009) showed that
craniospinal axis irradiation using HT yielded encouraging patient outcomes and acute toxicity profiles.
The increased conformity is most likely attributable to the large number of intensity modulated fields
delivered and to having a rotating radiation source synced with treatment couch movement to avoid
abutting individual fields.

Figure 1 A Helical Tomotherapy treatment machine is shown rotating as the couch passes through
the bore of the gantry (Mackie et al., 2003).
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1.1.1.3

Intensity Modulated Radiation Therapy with Electrons
Despite the advantages of HT, there remains a potential benefit of using electrons, especially for

superficial targets. One such benefit is the finite range of the electron. Electrons could reduce the overall
integral dose delivered to the healthy tissue. IMRT treatments often treat large volumes to low doses
because of the numerous beam angles. This could be problematic to long term survivors who could be at
risk of secondary radiation-induced tumors.
Several research groups have investigated the combination of IMRT with electrons. Chan et al.,
(2006a) at Memorial Sloan-Kettering Cancer Center investigated the feasibility of combining electrons
with IMRT for patients with extensive scalp lesions. They found that mixing IMRT with electrons
reduced the dose to the brain with the same dose conformity and homogeneity as the conventional plan in
the PTV. They suggested that IMRT with electrons is a viable treatment modality for these scalp lesions.
Chan et al., (2006b) also compared IMRT mixed with electrons and IMRT alone for malignant pleural
mesothelioma and found that while both techniques provided excellent target coverage and normal tissue
sparing, the addition of the electron beams improved the sparing critical structures.
Mu et al. (2004) compared IMRT with mixed beam (IMRT plus electrons) plans that were
manually optimized for various deep-seated tumors in the head and neck, and concluded that both
methods produced clinically acceptable plans. However, the integral dose outside the PTV was generally
lower with the mixed beam plans compared to IMRT plans. However, this study examined only deepseated target volumes in the head and neck region, and the mixed beam plan optimized by a manual
iterative process.
The results of preliminary studies (Surucu, 2009) have indicated that it may be possible to utilize
the finite range of electrons (a modality available from most linear accelerators) to spare adjacent critical
structures, while at the same utilizing the highly conformal doses of IMRT to improve dose
inhomogeneities in the PTV. What was unknown was how HT, a technique with some advantages over
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conventional IMRT, would compare to a mixed beam technique that utilized conventional IMRT and
electrons.
1.2

Parotid and Nasal Cavity Tumors
Two disease sites would make interesting candidates for a comparison of HT and IMRT mixed

with electrons due to their superficial locations: Parotid gland tumors and nasal cavity tumors. Irradiation
of parotid gland tumors can lead to complications from the many critical structures nearby. One such
serious late complication is xerostomia (dryness of the mouth), which can reduce the quality of the life for
the patient. Another is myelitis and necrosis of the spinal cord, which may lead to paralysis. Nasal cavity
tumors are also challenging to treat because of the brainstem, optic chiasm, retinas, lenses, and brain.
Both of these locations are superficial enough to take advantage of the electron‟s depth dose curve.
Carcinomas of both the parotid gland and nasal cavity are rare. According to the annual SEER
Cancer Statistics Review (www.Cancer.org, 2009), 6000 parotid gland and 2000 nasal cavity tumors are
diagnosed each year in the United States. Because of the proximity to critical adjacent sensitive
structures in the head and neck, the management of these malignancies has been challenging. For all nasal
cavity or paranasal sinus cancers combined, the relative 5-year survival (which is a way of comparing
survival of people who have the specific disease with those who do not) is 54%. Survival tends to worsen
as the stage increases -- for stage 1 disease, the 5-year relative survival is 83%, but for stage IV disease it
is only 25%. The outlook is slightly better for salivary gland cancers. For stage 1 the relative 5-year
survival rate is 96%, but for stage IV it is only 37% (www.cancer.org, 2009). There is a need to indentify
treatment approaches that improves these outcomes.
1.3

Statement of the Problem
Previously studies have compared


HT to conventional mixed beams in post-mastectomy chest wall (Ashenafi, 2006)



HT to IMRT in parotids (Lee et al., 2008)
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HT to mixed beam for total scalp (Orton et al., 2005; Chan et al., 2006b)



HT to conventional mixed beam for craniospinal (Penagaricano et al., 2009)

General conclusions from these studies are that HT is suitable and in many ways superior for a
variety of head and neck cases and that IMRT mixed with electrons could offer some potential advantages
over IMRT only plans. However, no published studies to date have compared helical tomotherapy to
advanced mixed beam techniques (IMRT in conjunction with electrons) for superficial head and neck
targets. Moreover there is general lack of guidance in the literature for constructing IMRT-electron plans
for superficial targets.
1.4

Hypothesis/Specific Aims
The hypothesis of the current study is that for select superficial head and neck cancers that helical

tomotherapy can plan improved dose homogeneity with equal or better normal tissue sparing than plans
that optimize a static IMRT field on top of a single unmodulated electron beam.
Aim 1: Generate a database of patients previously treated at our institution from superficial head
and neck cancers.


Search previously treated patients with Pinnacle treatment plans for superficial head and neck
tumors. The study will focus on, but not limited to, malignant paranasal and parotid tumors with
planning target volumes (PTVs) less than 5.5 cm from the surface. The primary diagnosis groups
to be searched will be major salivary glands, nasal cavity, maxillary sinus, and nose.



After the appropriate patients are selected, sensitive data specific to each patient will be
anonymized and placed into a Health Insurance Portability and Accountability Act (HIPAA)
compliant database.
Aim 2: Develop HT and mixed beam plans that best meet the treatment prescription.



Plan each HT treatment on the TomoTherapy Hi-Art planning system.
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Plan each mixed beam treatment on the Pinnacle treatment planning system by optimizing a
IMRT plan on top of an electron dose distribution.
Aim 3: Evaluate and compare each plan based on clinical, dosimetric, and biological endpoints.



For the clinical comparison, an American Board Radiology certified radiation oncologist will
review the HT and mixed beam plans and evaluate each using a multiple choice questionnaire
focusing on the clinical acceptability of each plan, reasons why a plan was preferred, and how the
HT plan compared to the mixed beam plan.



Compare metrics for dosimetric comparison, including dose volume histograms (DVHs) for
involved structures, the conformity index, dose homogeneity index, the volume of normal tissues
receiving low doses, and the minimum, maximum and mean dose to the planning target volumes
(PTVs) and organs at risk (OARs).



The biological evaluation will include a comparison of calculated tumor control probability and
the normal tissue complication probability for both plans.
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Chapter 2
2.1

Materials and Methods

Aim 1: Patient Database - Generate a Database of Patients Previously Treated at our Institution for
Superficial Head and Neck Cancers

2.1.1

Patient Selection Criteria
Five patients with superficial head and neck cancers were selected for comparison of helical

tomotherapy and advanced mixed beam (IMRT with electrons) plans. Mary Bird Perkins Cancer Center
(MBPCC) has maintained a computer archive of patient treatment plans since August 2000. This database
was searched for superficial head and neck cancers. The criteria for selecting patients for the study were
1) that the primary PTV did not extend medially beyond the therapeutic range of a 20 MeV electron
beam, which is approximately 5.5 cm in tissue, and 2) that CT scan data was readily available from a
separate archive maintained by on-site CT technologists. The CT scan data can be quickly exported from
the CT machine to the TomoTherapy workstation however, exporting from the Pinnacle workstation to
TomoTherapy is tedious and time consuming thus the reason for requiring readily available CT scan data.
The clinical record and verify system (Mosaiq, IMPAC Medical Systems, Sunnyvale, California)
maintains a database of patients treated at MBPCC. The print report function was used to query the
database for two primary diagnosis groups: 160.0 (nasal cavity/middle ear/auxiliary sinus) and 142.0
(major salivary glands). Of the primary diagnosis groups searched, 81 patients for nasal cavity and 77
major salivary gland (parotid gland) patients were returned. 6 nasal cavity and 8 major salivary glands
met the criteria. From these, 2 nasal patients and 3 parotid patients were chosen. PTVs with highly nonuniform depth were rejected in order to use a single energy electron field and avoid abutment issues.
Table 1 indicates the patients‟ diagnosis and staging (if applicable) location of the disease, sex, and
approximate age at initial consultation.
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Table 1 Relevant disease data for patients selected in the study

Patient

Staging

Disease
location

Sex

Age

T1N0M0
Unstaged

Right parotid
Left parotid

F
M

53
80

Unstaged

Right parotid
Left nasal
septum
Left nasal
septum

F

36

M

73

F

90

4

Intermediate grade
mucoepidermoid carcinoma
Squamous cell carcinoma
High grade adenoidcystic
carcinoma
Moderately differentiated
squamous cell carcinoma

T1-2N0M0

5

Squamous cell carcinoma

cT1N0M0

1
2
3

2.1.2

Diagnosis

Anonymization and Patient Data Import
The original Pinnacle treatment plans were restored from archived tape or disc to the research

Pinnacle workstation for mixed beam planning. During this process, the patient name and medical record
number were removed from the treatment plan and CT data set. Both the *.header, *.ImageSet, and
patient file were modified. The patient‟s name and medical record number were then replaced with a
numeric code which is linked to a master list of patients used for research and maintained by the project
director. This was done to maintain patient confidentiality in accordance with Mary Bird Perkins Cancer
Center‟s HIPPA protocol.
Along with the restored Pinnacle plans, CT data were sent directly from the CT scanner (GE
Discovery ST or Lightspeed) to the TomoTherapy planning station for HT planning. The original 512 x
512 datasets were resampled to 256 x 256, and unnecessary CT slices were cut from the dataset in order
to improve optimization and dose computation time.
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2.2

Aim 2: Treatment Plans - Develop HT and Mixed Beam Plans that Best Meet the Treatment
Prescription
All mixed beam plans were constructed using the Philips Pinnacle3 (Philips Medical Systems,

Bothell, WA) treatment planning system (version 8.1x). Helical tomotherapy plans were constructed
using TomoTherapy Hi-Art treatment planning system (version 3.1.2). Contours, planning methods, and
optimization methods are described below.
2.2.1

Contours
PTVs contours were generated by a physician in the original archived plans. Volumes for the

primary PTV were 355.4 cm3, 197.7 cm3, and 353.6 cm3 for parotid patients 1, 2, and 3 respectively; and
57.6 cm3, 28.69 cm3 for nasal cavity patients 4 and 5.
Most organs at risk (OARs) were generated by either the physician or the dosimetrist (evaluated
and modified by the physician if necessary) in the original plan. The OARs previously contoured for the
parotid patients were the contralateral parotid, eyes, lenses, optic nerve, and spinal cord. For some of the
patients, the physician contoured additional regions of interest based on the patient‟s previous medical
history, and PTV location. The auxiliary OARs were fifth cranial nerve, optic chiasm, auditory system,
lips, and brain. The OARs previously contoured for the nasal cavity patients were the spinal cord, eyes,
lenses, and optic nerves.
2.2.2

Bolus
For the parotid gland tumors, in order to provide a build-up of dose to the PTV near the skin

surface or to surgical scars in these post-operative patients, a tissue-equivalent bolus was contoured. The
bolus also served to compensate for missing tissue, around the ear. Without the bolus, the electron dose
contributions would be highly inhomogeneous due to a lack of scatter equilibrium, causing a decrease of
dose in the shadow of a protrusion and an increase in dose around its periphery (Hogstrom and Almond,
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2006). The bolus for the parotid patients was either contoured as a 0.5 cm or 1.0 cm thick (depending on
the depth of PTV, energy of electron beam, and OAR distal to the PTV) expansion to the skin, as seen in
Figure 2.

Figure 2. A Transverse and sagittal views through the PTV of patient 1(a), patient 2 (b), and
patient 3 (c). Water equivalent bolus of 0.5 cm (a) or 1.0 cm (b and c) thickness is placed over the
patient‟s skin. The PTVs for the patients can be seen color contoured inside the skin and the bolus
contoured outside.
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For the nasal cavity patients, in order to provide tissue compensation around the nose, a tissueequivalent bolus was contoured. The bolus was contoured over the nose (about 0.5 cm thick at the apex
of the nose) for patient 4 and was scanned in during CT for patient 5 (as seen in Figure 3 (b)). In order to
prevent any sharp edges in the electron field, the bolus was extended in a mushroom shape over the skin
collimation on the eyes (as seen in Figure 3 (a)). A 1.0 cm thick lead equivalent skin collimation was
contoured over the eyes to shield the lenses.

Figure 3. Boluses for nasal cavity patients are shown. On the left is patient 4 (a) that has a hand
contoured water equivalent bolus seen in purple with a 1.0 cm lead equivalent skin collimation seen
in gray. On the right is patient 5 (b) with the CT scanned bolus on the patient before the lead skin
collimation was added.
All contours were generated using the Pinnacle treatment planning system and copied to the HiArt planning system for HT planning and optimization. It should be noted that the optimization
algorithms for the two systems differ in the treatment of overlapping contours (an example would be the
contour for the lens of the eye overlapping with the contour of the eye). The Pinnacle planning system
optimizes for any voxels that overlap as if they belonged to both structures. On the other hand, for
structures within a particular class (i.e., PTVs or OARs), the TomoTherapy planning system uses a userdesignated priority system to determine which structure an overlapping voxel belongs, and used the
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corresponding dose constraint for that structure. For the patients in this study, the only OAR structure
overlaps were the lens with the eyes in the HT plans and the lens were given priority.
2.2.3

Dose Limiting Structures
For IMRT plans, higher than desired dose levels are sometimes produced in regions outside the

PTV and OAR contours. For these cases, dose limiting structures may be used to contain dose. Dose
limiting structures are used in inverse-planning methods such as HT and IMRT plans. They are
contoured in such a way that the dose distribution is constrained not to exceed a certain limit. An
example of a commonly used dose limiting structure is a ring. A ring normally surrounds the PTV as seen
below in Figure 4. By using a dose-shaping structure such as a ring, the optimization routine will reduce
peripheral hot spots and require similar dose contributions from each beam. For these cases a ring was
created by a 3 step process. 1) An ROI was created by radially expanding the PTV by 1.0 cm. 2) A
second ROI was created by radially expanding the PTV by 1.5 cm. 3) A final ROI called “ring” was
created which uses the larger (1.5 cm PTV expansion) ROI as the source and then avoid the interior of the
smaller (1.0 cm PTV expansion) ROI. The ring ROI was used for all mixed beam plans. HT plans did
not require a ring because a high modulation factor was not chosen.

For the IMRT planning component of the mixed beam plans, a hot spot would occasionally occur
outside of the PTV but not in an OAR. In those cases, a “hot spot” contour was drawn around the area of
increased dose and then used again in the optimization process to reduce the dose in that area. Hot spot
contours were not needed on the TomoTherapy plans.
2.2.4

Plan Parameters
Once all the contours and dose limiting structures were defined, pre-optimization plan parameters

values were set. Table 2 and 3 show a summary of the plan parameters values used for the HT and mixed
beam plans, respectively.
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Figure 4. Example of dose limiting structures surrounding the PTV (red contour is the PTV, green
contour is a hot spot, and blue contour is the ring)
Plan parameters were set to values most commonly used in the clinic to ensure that plan delivery would
not exceed normal treatment and optimization times.
2.2.4.1

Helical tomotherapy

2.2.4.1.1

Jaw width:

In HT, the primary beam is collimated longitudinally by the jaws. The „field width‟ parameter
adjusts the longitudinal extent of the treatment field (full width at half maximum) at the machine
isocenter. For all the TomoTherapy plans, the field width was set to the 2.45 cm jaw opening. This
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setting was used to achieve good dose conformity to the PTV in the superior-inferior direction of the
patient.
2.2.4.1.2

Pitch

Pitch is used to determine the amount of primary beam overlap along the longitudinal axis per
gantry rotation. The pitch is related to the field width by the equation:

𝑃𝑖𝑡𝑐ℎ =

𝐶𝑜𝑢𝑐ℎ 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑇𝑟𝑎𝑣𝑒𝑙𝑒𝑑 𝑝𝑒𝑟 𝐺𝑎𝑛𝑡𝑟𝑦 𝑅𝑜𝑡𝑎𝑡𝑖𝑜𝑛
𝐹𝑖𝑒𝑙𝑑 𝑊𝑖𝑑𝑡ℎ

(1)

In order to minimize the HT thread effect (Kissick et al., 2005), pitch values should be chosen
such that

𝑃𝑖𝑡𝑐ℎ = 0.86 ∗

1
, 𝑤ℎ𝑒𝑟𝑒 𝑛 ∈ 0,1,2, . .
𝑛

(2)

A larger pitch value decreases the amount of beam overlap and produces a slower gantry period.
A smaller pitch value increases the amount of beam overlap and produces a faster gantry period. A pitch
of 0.287 was ultimately chosen (n=3), in order to maintain DVH uniformity for tumor structures and keep
the treatment times reasonable.
2.2.4.1.3

Modulation factor

The modulation factor is used by the optimizer to determine the range of intensity values of the
primary beamlets. The modulation factor is calculated as the ratio of the greatest beamlet intensity for all
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projections to the average intensity for all non-zero beamlets. The modulation factor effects the gantry
period since beamlet intensity is affected by leaf open time. Essentially, this means a higher modulation
factor increases the range of beamlet intensity (giving the optimizer more control over the dose
distribution), however at the expense of a longer treatment duration. In this work, a maximum
modulation factor of 3.0 was used which is a standard value used in the clinic.
2.2.4.1.4

Dose grid

The dose grid resolution was set to “normal” making the dimensions of the dose grid (3.91 x 3.91
x 2.5 mm3). By selecting the normal dose grid, dose is calculated on the planning CT dataset that has
been downsampled by a factor of 2. The CT data was imported into the TomoTherapy planning system
at 256 x 256 pixel resolution; therefore, the dose grid resolution is (128 x 128).

Table 2. TomoTherapy plan parameter specifications.
Field width

2.45 cm

Pitch

0.287

Planning modulation factor
Dose grid resolution

3
normal (3.91 x 3.91 x 2.5 mm3)

2.2.4.2

Mixed beam

2.2.4.2.1

Beam orientation

Pinnacle treatment plans were designed as a combination of a 5 or 7 field 6-MV IMRT (5 for the
nasal cavity and 7 for the parotid gland) plan optimized on top of a single enface electron beam of energy
16 MeV (used on patient 2 to treat a shallow parotid tumor) or 20 MeV (all others). IMRT field
configurations for a parotid patient can be seen in Figure 5. The enface electron beam was blocked and
the PTV exposed with approximately a 1 cm margin. The exception to this was patient 3 (multiple
PTVs); for that patient, the upper two PTVs were exposed and the lower PTV blocked to avoid treating
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the lower neck. The lower PTV dose was primarily delivered by the supplementary IMRT fields. IMRT
photon fields were roughly arranged around the body approximately every 30 degrees. When choosing
beam angles, consideration was given to both entry and exit of beams in the patient.

Figure 5 Transverse slice for patient 1with central beam axis orientation shown with straight lines.
PTV is shown in red colorwash.
2.2.4.2.2

Beam ratios

Historically, mixed beam plans often involved a combination of photons and electrons with
electrons, usually heavily in favor of electrons (Tapley, 1976). However it was unknown what ratio
would be optimal when mixing electrons and IMRT. Therefore, seven different ratios of IMRT to
electrons were investigated. The ratios examined are listed below and are calculated as a ratio of the dose
to R100 of the electron beam. It should be noted that, for the purposes of this study, the IMRT-only and
electron-only plans were considered subsets of the mixed beam planning approach.


1:0 (IMRT only)



2:1



1:1



1:2
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1:3



1:4



0:1 (Electron only)

The dose grid resolution for the IMRT with electrons plans was set to 4.0 x 4.0 x 4.0 mm3 on the
Pinnacle treatment planning system. The extent of the dose grid was manually selected to cover OARs
and PTVs plus a wide margin including 5 cm past this range.

Table 3. Plan parameter specifications.
Parameter
Number of IMRT beams (energy)
Number of electron beams (energy)
Lead skin collimation for electron beam
Water equivalent bolus used for HT

2.2.4.3

Parotid patients
7 (6MV)
1 (20MeV or 16 MeV)
No
Yes (to boost surgical scar)

Nasal cavity patients
5 (6 MV)
1 (20 MeV)
Yes
No

Optimization and Dose Calculation
The physician prescription for the planning target volumes were kept the same for the both the

TomoTherapy plan and the mixed beam plan. The prescribed PTV dose ranged from 54 Gy to 70 Gy for
the range of patients chosen for this study.
After defining the planning parameters, the treatment plans were optimized, and final doses
calculated. Both planning systems use target and avoidance structure constraints in their optimization
process. The planning goals for the HT plan and the mixed beam plan were kept as close as possible.
Table 4 shows the optimization objectives for HT and the IMRT course of the mixed beam plans for the
parotid tumor patients; Table 5 shows similar data for the nasal cavity tumor patients.
The optimization procedure for the mixed beam plans was as follows. For each trial, the ratio of
the prescribed dose to R100 for the electron beam was chosen. The electron beam dose contributions were
computed using an electron 3D algorithm with heterogeneous density correction. Following the dose
computation for the electron beam, the dose constraints for the OARs and PTVs were set for the IMRT
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photon fields. The intensity of the IMRT beams was modulated using a pencil beam optimization process
set with a max number of iterations of 40. A collapsed cone convolution dose calculation, which is more
accurate but slower than the pencil beam model, was computed at the 15th and final iterations. The
majority of plans reached an optimal solution before the 40th iteration (Stopping tolerance was set as 1e05).

Table 4 Dose objectives and planning prescriptions for parotid patients for targets and organs at
risk for HT and mixed beam plans.
Variable
Targets:
Prescription
(Isocenter dose in Gy)
Planning goals
PTV
Minimum dose (Gy)/target volume (%)
Maximum dose
Minimum dose
Organs at risk:
Maximum dose (Gy)/target volume (%)
Spinal cord
Parotidcon
Eye isp
Eyecon
Lensips
Lenscon
optic nerve ips
Auditoryips
Brain stem
Lips
Optic chiasm
Fifth cranial nerve
Spinal cord + margin

Patient 1

Patient 2

Patient 3

59.4

65.0

63.9

59.4/98
62.0
59.0

65.0/98
66.0
64.0

(Primary; Secondary; Tertiary)
63.9/98; 60.0/98; 54.0/98
64.0; 61.0; 55.0
62.5; 59.0; 53.0

42.0
9.0/5
3.0
3.0

41.0
15.0
12.0
12.0
2.0
2.0

41.0
15.0
5.0
5.0

50.0
60 & 50/30
49.0
15/10

12.0
50.0
63.9 & 52.0/98
45.0

At the end of the optimization, the fluence maps generated were converted into MLC leaf
sequences using a k-means clustering conversion with a maximum of 10 levels and a 3% error tolerance.
The conversion constraints were that the minimum segment area set to 2 cm2 and minimum segment
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monitor units of 2, which are typical values found in the MBPCC clinical head and neck IMRT
optimization protocol. The resulting plan was reviewed and the process was repeated after adjusting the
weighting of each dose constraint as necessary. In general, the weighting of the OARs were set as high as
possible without degrading the dose distributions to the PTV or surrounding normal tissue. Finally a
segment weight optimization was done to ensure that optimal weighting of each segment after the
conversion.
The optimization procedure for the HT plans was as follows. The TomoTherapy Hi-Art system
optimization for PTVs was controlled using three dose constraint goals: 1) the percent volume of the
primary PTV receiving a set dose. In this study that value was 98% of the PTV volume receiving the
prescription dose. This is a hard constraint, in that the optimization will only return DVHs that meet this
constraint. 2) The maximum dose delivered to the PTV and 3) minimum dose to the PTV (these values
can be found in Table 4 and Table 5). OARs were controlled by the maximum dose to that OAR and the
volume of the OAR to receive a certain dose. Similar to the mixed beam plans, the optimization process
uses importance and penalties as a relative weight to update leaf intensity values during the iterations of
the optimization.
HT plans were optimized using beamlet mode, which uses a pre-computed dose distribution for
each beamlet and convolves the dose spread kernel with an interaction point. After roughly 40 iterations,
the optimization was paused. Penalties and the importance of the PTV and OARs were evaluated and
adjusted as needed. The optimization was then restarted and allowed to continue for another 20 to 40
iterations. This process was repeated until acceptable results were achieved in the DVH.
When the PTV reached the point where it would no longer improve in conformity and was within
the desired objectives, the OARs were increased in weighting until they adversely affected the PTV‟s
dose objectives. When the PTV was within the desired objectives and OARs reduced to clinically
acceptable values, the HT optimization process was terminated. Table 6 lists typical PTV, OAR, and
ROI objectives upon completion of optimization. Finally, a final full scatter calculation was performed.
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Table 5. Dose objectives and planning prescriptions for nasal cavity patients for targets and organs
at risk for HT and mixed beam plans.
Variable
Targets:
Prescription
(isocenter does in Gy)
Planning goals
Primary PTV
Minimum dose (Gy)/target volume (%)
Maximum dose
Minimum dose
Organs at risk:
Maximum dose (Gy)/target volume (%)
Spinal cord
Right eye
Left eye
Right lens/Anterior of eye
Left lens/Anterior of eye
Right optic nerve
Left optic nerve

Patient 1

Patient 2

70.0

65.0

70.0/98
71.0
69.0

65.0/98
65.8
64.0

41.0
35.0
35.0
12.0
12.0
45.0
45.0

41.0
20.0
20.0
5.0
5.0

Table 6 Typical PTV, OAR, and ROI constraints upon completion of optimization
Structure

PTV
Contralateral
Parotid
Spinal Cord
Eyes
Brainstem
Ring

Importance

50
1

Max
Dose
(Gy)
62
12

5
2
2
1

42
3
49
35

Max
Dose
Penalty
4
6
25
1
3
1

DVH
Vol
(%)
98
5
10
10
40
10

DVH
Dose
(Gy)
59.4
5
10
2
30
34

DVH
Penalty
1
2

Min
Dose
(Gy)
59.0
-

1
1
1
1

-

Min
Dose
Penalty
1
-

After the final dose full scatter calculation, the dose matrix from the Hi-Art system was imported into the
Pinnacle patient database such that the isodose plots and DVHs from the HT plan could be displayed and
compared with mixed beam plans.
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2.3

Aim 3: Evaluation of Endpoints - Evaluate and Compare each Plan Based on Clinical, Dosimetric,
and Biological Endpoints.

2.3.1

Clinical Evaluation
In order to evaluate the plans on their clinical effectiveness, a radiation oncologist compared and

rated each plan. The radiation oncologist reviewed each patient‟s isodose distribution and DVHs, and was
then asked to fill out a worksheet/questionnaire related to the quality of the plans (located in the Appendix
A).
In the questionnaire, the radiation oncologist was first asked to rate the clinical utility of each
plan using the following choices: acceptable, marginally acceptable, indifferent, marginally unacceptable,
and unacceptable. Second, the radiation oncologist was asked to assess the TomoTherapy plan relative to
the best IMRT with electron plan (this included IMRT-only and electron-only plans} using the following
choices: superior, marginally superior, indifferent, marginally inferior, and inferior. Next, the radiation
oncologist was asked to list the reasons why he/she found the plan he chose superior. Finally, a margin
was left on the questionnaire for additional comments.
2.3.2

Dosimetric Evaluation
In order to evaluate the dose distribution in the plans, several dosimetric endpoints were

computed. The dosimetric endpoints of interest in this study include:


DVHs for each PTV and OAR



Target volume coverage



Conformity index (CI)



Dose homogeneity index (DHI), the difference in PTV dose that 1% of the volume and
99% of the volume receives



Maximum dose, mean dose, and relevant volume of OAR receiving a set dose based on
complications
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DVHs provide a summary of the entire dose distribution for a target volume and OARs. It
effectively displays the percent of volume of the structure that may have been over and/or under-dosed.
The DVHs, in conjunction with the spatial information contained in an isodose dose distribution, provide
tools needed to compare competing plans.
Target volume coverage was computed for all planning target volumes. Maximum dose was
defined as the highest dose to 1% of the target volume, Dmax(v1%). Minimum dose was defined as the
lowest dose to 99% of the target volume, Dmin(v99%) or greater. This was done to avoid artificially small
hot or cold spots that might result from dose algorithm approximations or dose grid placements, as these
inhomogeneities spots might not be considered clinically meaningful.
The conformity index (CI) is a tool for scoring and evaluating different treatment plans for the
same patient. CI has been defined in different ways (Feuvret et al., 2004). However, CI for this study
was computed using the method of Paddick (Paddick, 2000), to take into account the dose coverage of the
PTV. The method combines the proportion of the target volume covered by the prescription isodose with
the proportion of the prescription isodose within the target volume, as described following equation:

𝐶𝐼 =

𝑇𝑉𝑃𝐼𝑉 2
,
𝑇𝑉 × 𝑃𝐼𝑉

(3)

where TV is the volume of the target, TVPIV is the volume of the target within the prescribed isodose
value, and PIV is the volume covered by the prescribed isodose value. In an ideal treatment plan, the CI
would equal to 1, with values less than 1 reflecting less conformal plans.
In order to quantify the dose uniformity in the PTV, difference between the maximum dose (that
is the dose that only 1% of the PTV receives) and the minimum dose (that is the dose that 99% of the
PTV receives) was computed. The difference in dose was then divided by the desired target dose, and
this value is known as the dose homogeneity index (DHI). DHI was defined as (Dmax(v1%)- Dmin(v99%))/ Dp
where Dmax(v1%) and Dmin(v99%) represent the doses to 1% and 99% of the PTV, respectively. For example,
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D99% indicates that at least 99% of the target volume receives dose, D, and hence Dmax(v1%) and Dmin(v99%)
are considered to be maximum and minimum doses, respectively. Dp is the desired target dose. Smaller
values of the DHI represent more uniform dose distributions and are thus better. This metric will be used
to test the hypothesis.
2.3.3

Biological Evaluation
Dosimetric evaluations effectively convey the amount of dose deposited, however a biological

evaluation can give information related to how the dose might affect the patient. Radiobiological metrics
such as normal tissue complication probability (NTCP) and tumor control probability (TCP) were used to
compare plans. An in-house radiobiological program developed by Tae Ku Lee, Ph.D., research medical
physicist at our clinic, was used to compute NTCP and TCP values. NTCP values were computed using
the Lyman-Kutcher-Burman probit model (Lyman, 1985) (Kutcher and Burman, 1989) such that

𝑁𝑇𝐶𝑃 =

1
2𝜋

𝑡

1

2

𝑒 −2∗𝑥 𝑑𝑥

(4)

−∞

and

𝑡=

𝐷 − 𝑇𝐷50 (𝑣)
,
𝑚 ∗ 𝑇𝐷50 (𝑣)

(5)

where D is the dose that uniformly irradiates the volume, TD50(v) is the dose that produces a 50%
complication rate for uniform irradiation of the fractional volume, m is a modeling parameter that sets the
steepness of the dose response curve. v is the ratio of organ uniformly irradiated and is defined as
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𝑣=

𝑉
𝑉𝑂𝐴𝑅

,

(6)

V is the volume of the OAR uniformly irradiated and Voar is the volume of the OAR.

𝑇𝐷50 𝑣 =

𝑇𝐷50 (1)
,
𝑣𝑛

(7)

where n is a parameter to account for volume effects for an organ. Small values of n indicate a smaller
effect from the volume irradiated such as in a serial structure like the spinal cord, which can be damaged
with high doses in small volumes. Values of n, m, and TD50 for OARs in this work were taken from
available literature (Emami et al., 1991; Burman et al., 1991; Roesink et al., 2001) and are shown in
Table 7.

Table 7. Values of the biologic parameters used for calculation of normal tissue complications
probabilities(Burman et al., 1991; Roesink et al., 2001; Eisbruch et al., 1999)
Organ (endpoint)

n

Spinal cord (myelitis/necrosis)
0.05
Optic nerve (blindness)
0.25
Eye/retina (blindness)
0.2
Lens (cataract)
0.3
Parotid (xerostomia)
0.7
Parotid (salivary flow reduction to <25% at 6 wk) 1
Parotid (salivary flow reduction to <25% at 1 year) 1

M

TD50 (whole organ)

0.175
0.14
0.19
0.27
0.18
0.54
0.45

66.5
65
65
18
46
31
39

TCP values were computed for the primary PTV using the standard Poisson doseresponse model (Steel, 2002) assuming homogeneous tumor cell distribution:
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𝑇𝐶𝑃 = 𝑒𝑥𝑝 −𝜌 ∗ 𝑇𝑉 ∗ 𝑒 −𝛼𝐷−𝛽𝑑𝐷 + ln 2

(𝑇𝑡𝑜𝑡 − 𝑇𝑘 )
,
𝑇𝑝

(8)

where ρ is the average density of tumor cells in the target, TV is the tumor volume, α is the cell
radiosensitivity, β is the effectiveness/lethality of radiation, D is the total treatment dose, d is the
dose per fraction, Ttot is the overall time of treatment, Tk is the “kick-off” time for the cell
proliferation, and Tp is the average doubling time of clonogenic cells in the tumor. Parameters
used in the TCP calculation are shown in Table 8 and were taken from available literature
(Fowler, 2001; Wigg, 2001; Lee et al., 2008).

Table 8. Parameters selected to calculate TCP for head and neck patients (Wigg, 2001; Fowler,
2001)

ρ
α
Β
Tk
Tp

2.3.4

average density of tumor cells in the
target
cell radio sensitivity
the effectiveness/lethality of radiation
time for cell proliferation
average doubling time of clonogenic cells

1.5 x 104 cm-3
0.35 (Gy-1)
0.035 (Gy-2)
28
3

Secondary Cancers

In order to estimate the secondary cancer probabilities, measurements of the volume of
normal tissue receiving lower doses were made. The volume of tissue receiving between 5 and
25 Gy is thought to be significant because of the high estimated solid cancer incidence within
that dose interval (Schneider and Kaser-Hotz, 2005). Figure 6 shows a plot of cancer incidence
per 104 per year for solid tumor induction as a function of dose. From this figure, note that at
higher doses there is a lower chance of secondary cancer induction due to mutated cells
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becoming sterilized. The volume of tissue receiving between 25 Gy and 5 Gy provides a
general estimation of secondary cancer induction.

Figure 6 Estimated solid tumor induction as a function of homogenous organ dose for normal tissue
based on the Schneider‟s model (Schneider and Kaser-Hotz, 2005)
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Chapter 3
3.1

Results

Convention for Presenting Results of Each Patient
The format for presenting the results is the same for all patients. For each patient, the results are

presented in the following order:


Review of patient diagnosis and critical patient information



Isodose distribution comparison



DVH comparison



Radiation oncologist‟s review



Dose statistics of the PTV and the resultant TCP



Dose statistics of the OARs and the resultant NTCPs and secondary cancer induction

Isodose distributions are shown in orthogonal planes at the geometric center of the primary PTV.
The isodose distributions are displayed for the TomoTherapy, IMRT, and the mixed beam ratio judged to
exhibit the best balance of PTV coverage and OAR sparing. A full set of isodose distributions for all
mixed beam plans are shown in Appendix B. The isodose lines are displayed in units of cGy and
correspond to the following values:


115% of the PTV prescription (maroon)



105% of the PTV prescription (yellow)



100% of the PTV prescription (red)



95% of the PTV prescription (purple)



45 Gy, a critical dose for the myelitis and necrosis of the spinal cord (green)



35 Gy, a critical dose for blindness for the eyes (steel blue)



25 Gy, doses between 5 and 25 Gy have a high probability of solid tumor induction,
(grayscale)



5 Gy, see above, (olive)
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The DVH comparison for each patient begins with a description of all mixed beam plans. This is
followed by a comparison of DVHs for the HT, IMRT, and select mixed beam plans.
3.2

Patient One - Parotid

3.2.1

Patient Specific Information
A 53 year old female was diagnosed to have intermediate grade mucoepidermoid carcinoma in

the right parotid gland, stage T1N0M0. Patient had close margins following surgery and has primarily a
risk of recurrence within the parotid bed. She was at low risk of developing distant metastases. 59.4 Gy
at 2 Gy per fraction was delivered using IMRT.
3.2.2

Isodose Distributions
Isodose distributions for HT, IMRT (1:0), and a selected mixed beam plan (1:2 ratio) are

displayed in Figures 7-9. The white crosshairs in the CT images indicate the position of the orthogonal
planes and the red colorwash region indicates the primary PTV. The red isodose line represents the
desired prescription dose (59.4 Gy) to the primary PTV. Dose statistics for the isodose distributions can
be found in Table 9 for the PTV and Table 11 for the critical structures.
3.2.2.1

HT
The HT isodose distribution showed more conformal coverage of the PTV than the IMRT and

mixed beam plans. Hot spots in the HT plan were small (~5%) and were generally located along the skin
surface. These 5% hotspots (62.4 Gy), are observable as the yellow isodose lines. In Figure 7, can be
seen both the transverse and coronal slices.
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Figure 7 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through the
center of the PTV for patient 1 for the TomoTherapy plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as in red colorwash.
No cold spots were noted in the PTV in the HT plan. The HT plan showed a good dose fall off towards
the contralateral side of the head where the plan was optimized to avoid the contralateral parotid gland.
The 25 Gy isodose line can be seen wrapping around the contralateral parotid in the HT plan as a result of
the optimization. Near the PTV, the dose fall off for the HT plan was similar to both the IMRT and the
mixed beam plan.

31

Figure 8 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through the
center of the PTV for patient 1 for the IMRT (1:0) plan. The white crosshair indicates the position
of the planes shown. The PTV is displayed as in red colorwash.

The HT plan showed a significantly larger area of tissue outside the PTV receiving a dose lower
than 35 Gy compared to the mixed beam plan. However the volume of normal tissues receiving between
25 Gy and 5 Gy in the HT plan was less than in the IMRT and mixed beam plan.
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3.2.2.2

IMRT/Mixed Beam

Figure 9 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through the
center of the PTV for patient 1 for the IMRT + electron (1:2) plan. The white crosshair indicates
the position of the planes shown. The PTV is displayed as in red colorwash.
The IMRT (Figure 8) and selected mixed beam (Figure 9) isodose distributions showed distinct
hot and cold spots. The IMRT plan, similar to the HT plan, shows two 5% hot spots near the surface on
the transverse slice but also shows small hot spots intermittently throughout the PTV and hot spots at the
anterior and posterior edge of the foramen magnum. For the mixed beam plan, a 5% hot spot is visible
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on the posterior curvature of the neck. The dose to the medial edge of the PTV near the spinal cord in the
IMRT and mixed beam plan falls below the prescription dose (~5% cold spot), likely a outcome of
constraining dose to the spinal cord, which abuts the PTV. In addition, the prescription isodose line for
the mixed beam plan doesn‟t cover the entire PTV at the anterior edge, resulting in a slight (95%
coverage) cold spot.
The IMRT and mixed beam plan isodose distributions exhibited similar fall off near the PTV
compared the HT plan, but a sharper dose fall off away from the PTV. The three plans show similar dose
fall off near the PTV with the mixed beam plan showing a slightly faster fall off to 35 Gy (steelblue line)
than IMRT or HT.
3.2.3
3.2.3.1

DVH Comparisons
All mixed beam plans
DVH comparisons for the PTV and OARs for the mixed beam plans are shown in Figure 10 and

Figure 11, respectively. The mixed beam plans all showed similar PTV dose volume coverage with the
exception of the 0:1 ratio (electron only) plan, which was significantly less uniform. Of the mixed beam
plans, the 2:1 ratio (black line) had the steepest curve (an indication of conformity), while the 1:1 ratio
(red line) had the worst, excluding the electron only.
For the OARs, the 0:1 ratio plan gave the lowest mean and max dose to the brainstem and the
contralateral parotid, followed by the 1:4 ratio mixed beam plan. All mixed beam plans showed similar
dose-volume relationships for the brainstem over 50 Gy. For the contralateral parotid gland, the 2:1 and
1:1 mixed beam similarly gave a mean dose that was larger than the other mixed beam plans. The 1:2
ratio plan showed good balance of PTV coverage and critical structure sparing.
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Figure 10 DVHs for patient 1 for the PTV of the mixed beam plans
3.2.3.2

Select mixed beam, HT, and IMRT
DVHs for the PTV and OARs for the HT, IMRT, and selected mixed beam (1:2 ratio) are shown

in Figure 12. The HT plan showed a smaller volume of PTV receiving greater than and less than the
prescription dose of 59.4 Gy compared to the IMRT and mixed beam plans (this is reflected in the isodose
of Figure 7). The HT plan showed a more uniform dose distribution in the PTV.
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Figure 11 DVHs for patient 1 for the OARs of the mixed beam plans
For the OARs, the HT and mixed beam plans had a similar maximum spinal cord, which was
lower than maximum dose from the IMRT plan. The volume of brainstem receiving above 50 Gy was
lowest for the HT plan. However, the mixed beam plan gave the lowest integral dose for the brainstem.
The brainstem DVHs cross at about 40 Gy. The selected mixed beam plan showed less volume of
brainstem receiving over 50 Gy than the IMRT plan. Overall, the HT plan showed good sparing of the
spinal cord and the brainstem (above 40 Gy).
3.2.4

Radiation Oncologist Review
A radiation oncologist evaluated the clinical acceptability of the HT, IMRT, and mixed beam

plans and found the HT plan to be clinically acceptable, was indifferent about the IMRT plan, and found
the best mixed beam ratio to be marginally acceptable.
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Figure 12 DVHs for patient 1 for the PTV and OARs for the HT, IMRT, and selected mixed beam
plans

A complete list of individual plan reviews can be found in Appendix A. After reviewing the
dose distributions and DVHs for all the plans, he ranked the TomoTherapy plan marginally superior to the
mixed beam plan. PTV coverage was listed as a reason for preferring HT plan over the mixed beam. The
radiation oncologist suggested that a larger volume of brainstem receiving a high dose may be of concern.
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3.2.5
3.2.5.1

Dose Statistics for the PTV and TCP
All mixed beam plans
Table 9 gives the dose statistics for the PTV for the mixed beam plans. The TCP values were

comparable (within ± 0.1% of 98.6% tumor control) for all the plans, except for the electron-only plan
(95.6%). Conformity index (CI) was highest for the 2:1 ratio plan (0.852) followed closely by the IMRT
plan with 0.842. CI generally decreased as more electrons were introduced and was lowest (worst) for the
electron-only plan (0.656). However, the addition of a small IMRT component to the electron plan
significantly improved CI (0.814 for the 1:4 ratio). Dose homogeneity index was similar for all mixed
beam plans, with a high value of 0.102 (worst) and a low value of 0089 (best) for the 1:1 and 1:2 ratios,
respectively.

Table 9 Dose statistics for the PTV for the mixed beam plans for patient 1
PTV – Patient 1
Plan
TCP (%)
1:0 (IMRT) 98.6
2:1
98.7
1:1
98.6
1:2
98.7
1:3
98.7
1:4
98.7
0:1
95.6

3.2.5.2

CI
0.842
0.852
0.798
0.832
0.818
0.814
0.656

DHI
0.097
0.09
0.102
0.089
0.094
0.099
0.271

Dmax (Gy)
62.7
62.3
63.2
62.9
63
63.1
68.1

Dmin (Gy)
56.9
57.3
57.1
57.6
57.5
57.3
52.0

Select mixed beam, HT, and IMRT plans
Table 10 gives the dose statistics for the PTV from the HT, IMRT, and select mixed beam plans.

The TCP values were within ± 0.1% of 98.6% tumor control. The CI for the IMRT plan was slightly
lower than the HT and mixed beam plans (0.842 compared to 0.851 and 0.832, respectively). The HT
plan showed a lower DHI value, indicating the HT plan was more homogeneous over the PTV.
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Table 10 Dose statistics for the PTV for the HT, IMRT, and select mixed beam plan for patient 1
PTV – Patient 1
Plan
HT

TCP (%)
98.5

CI
0.851

DHI
0.063

Dmax (Gy)
63.2

Dmin (Gy)
59.4

1:0
1:2

98.6
98.7

0.842
0.832

0.097
0.089

62.7
62.9

56.9
57.6

3.2.6

Dose Statistics for OARs and NTCP

Table 11 Dose statistics for the OARs for the mixed beam plans for patient 1
Critical Structures – Patient 1
Contralateral
parotid
Plan
1:0
2:1
1:1
1:2
1:3
1:4
0:1

Dmean
7.3
6.7
6.9
5.0
4.9
4.9
3.4

Spinal
cord
NTCP(%)
7.9
7.3
7.5
6.0
6.0
5.9
4.9

Dmax NTCP(%)
45.3
0.5
46.6
0.6
48.1
0.5
43.8
0.4
44.2
0.4
43.9
0.3
45.0
0.4

Brainstem
Dmax
55.8
55.6
56.1
56.5
56.4
56.4
51.8

Lips
NTCP(%) Dmax
0.1
24.4
0.1
18.3
0.1
14.6
0.1
14.7
0.1
14
0.1
17.3
<0.1
13.3

Contralateral Ipsilateral
eye
eye
Dmax
2.9
3.2
3.6
3.5
3.5
3.6
3.6

Dmax
4.4
4.0
4.1
3.7
3.7
3.8
3.9

Table 12 Dose statistics for the OARs for the HT, IMRT, and select mixed beam plan for patient 1
Critical Structures – Patient 1
Contralateral
parotid
Plan
HT
1:0
1:2

Dmean
6.0
7.3
5.0

Spinal
cord
NTCP(%)
6.8
7.9
6.0

Dmax NTCP(%)
43.2
0.3
45.3
0.5
43.8
0.4

Brainstem
Dmax
59.6
55.8
56.5
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Lips
NTCP(%) Dmax
0.1
23.1
0.1
24.4
0.1
14.7

Contralateral Ipsilateral
eye
eye
Dmax
6.9
2.9
3.5

Dmax
9.1
4.4
3.7

3.2.6.1

Contralateral parotid

3.2.6.1.1

All mixed beam plans

Table 11 gives the dose statistics for the contralateral parotid for the mixed beam plans. Mean
dose and NTCP of salivary flow reduction to less than 25% at six weeks was computed. Mean dose
values ranged from 7.3 Gy for the 1:0 (IMRT only) to 3.4 Gy for the 0:1 (electron only). For all but the
1:1 plan, there is a gradual reduction in the mean dose and the NTCP as electrons were introduced into the
mixed beam ratio. However, adding electron beyond the 1:2 ratio only provided slight differences in the
mean dose and the NTCP.
3.2.6.1.2

Select mixed beam (1:2), HT, and IMRT plan

Table 12 gives the dose statistics for the contralateral parotid for the HT, IMRT, and select mixed
beam plan. Mean dose and NTCP of salivary flow reduction to less than 25% at six weeks was
computed. Mean dose values were 6.0 Gy for HT, 7.3 Gy for IMRT, and 5.0 Gy for the select mixed
beam plan. The mixed beam plan delivered 1 Gy less to the contralateral parotid than the HT plan,
corresponding to a reduction in NTCP of about 1% in the contralateral parotid.
3.2.6.2

Brainstem

3.2.6.2.1

All mixed beam plans

Table 11 gives the dose statistics for the brainstem for the mixed beam plans. Maximum dose
and NTCP of necrosis was computed. Maximum dose values ranged from 56.5 Gy for the 1:2 ratio to
51.8 Gy for the 0:1 (electron only) plan. NTCP for necrosis was similar for plans at 0.1%. Adding
increased electron ratios did not reduce the NTCP for the brainstem (except for the electron only plan).
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3.2.6.2.2

Select mixed beam, HT, and IMRT plan

Table 12 gives the dose statistics for the brainstem for the HT, IMRT, and select mixed beam
plan. Maximum dose and NTCP of necrosis was computed. Maximum dose values were 59.6 Gy for
HT, 55.8 Gy for IMRT, and 56.5 Gy for the select mixed beam plan. The NTCP values for the HT and
IMRT plan were similar (0.1%), and were near that of the mixed beam plan (0.1%).
3.2.6.3

Spinal Cord

3.2.6.3.1

All mixed beam plans

Maximum dose and NTCP of necrosis/myelitis was computed. Maximum dose values ranged
from 48.1 Gy for the 1:1 ratio to 43.8 Gy for the 1:2 ratio. NTCP for necrosis/myelitis was highest for the
2:1 plan at 0.6% and lowest for the 1:4 ratio plan (0.3%). There did not appear to be a strong coloration
between increased electron involvement and decreased risk of a spinal cord complication.
3.2.6.3.2

Select mixed beam, HT, and IMRT plan

Table 12 gives the dose statistics for the spinal cord for the HT, IMRT, and select mixed beam
plan. Maximum dose and NTCP of necrosis/myelitis was computed. Maximum dose values to the spinal
cord were 43.2 Gy for HT, 45.3 Gy for IMRT, and 43.8 Gy for the select mixed beam plan. The NTCP
values for the HT and select mixed beam plan were similar (0.3% and 0.4% respectively) and the IMRT
plan‟s NTCP was slightly higher than HT and mixed beam at (0.5%).
3.2.6.4

Eyes and Lips

3.2.6.4.1

All mixed beam plans

Table 11 gives the dose statistics for the lips and eyes for the mixed beam plans. Maximum dose
was computed for these OARs. The maximum dose to the lips was lower with the mixed beam and
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electron only plans than the IMRT only plan. As expected, the dose to the ipsilateral eye was slightly
higher than the contralateral eye. The IMRT only plan gave the lowest contralateral eye dose (2.9 Gy) but
also gave the highest ipsilateral eye dose (4.4 Gy).
3.2.6.4.2

Select mixed beam, HT, and IMRT plan

Table 12 gives the dose statistics for the lips and eyes for the HT, IMRT, and select mixed beam
plan. Maximum dose was computed. Maximum dose values for the lips were similar for the HT and
IMRT plans (23.1 Gy and 24.4 Gy respectively), and were higher than the select mixed beam plan (14.7
Gy). Maximum dose to the eyes was higher with HT than either IMRT or the select mixed beam plan.
3.2.7

Non-specific Normal Tissue
The normal tissue volume receiving between 5 and 25 Gy for this patient was 1129 cm3 for the

HT plan, 1232 cm3 for the IMRT plan, and 1183 cm3 for the mixed beam plan. The difference in volume
between the HT and the mixed beam plan was 54 cm3. Normalizing the volumes to the HT plan, the
mixed beam plan gave 105% volume.
3.3
3.3.1

Patient Two - Parotid
Patient Specific Information
A 80 year old male was diagnosed to have squamous cell carcinoma in the left preauricular area,

unstaged. He received postoperative radiotherapy delieverd primarily with 12 MeV to 65 Gy in 32
fractions.
3.3.2

Isodose Distributions
Isodose distributions for HT, IMRT (1:0), and the selected mixed beam plans (1:1 ratio and 1:4

ratio) are displayed in Figure 13-16. The white crosshairs in the CT images indicate the position of the
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orthogonal planes and the red colorwash region indicates the primary PTV. The red isodose line
represents the desired prescription dose (65.0 Gy) to the primary PTV. Dose statistics for the isodose
distributions can be found in Table 14 for the PTV and Table 16 for the critical structures.

Figure 13 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 2 for the TomoTherapy plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as in red colorwash
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3.3.2.1

HT
The HT isodose distribution showed a more conformal coverage of the PTV than the IMRT and

mixed beam plans. No hotspots greater than 5% were seen in the HT plan.

Figure 14 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 2 for the IMRT plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as in red colorwash

44

The red isodose line (the desired prescription dose) closely covers the PTV in comparison to the IMRT
and mixed beam plans. The HT plan showed a slower distal fall off to the 45 Gy (green isodose line) than
the IMRT or mixed beam plans. Also, the HT plan showed a larger area of normal tissue outside the PTV
receiving a dose lower than 35 Gy compared to the IMRT and mixed beam plans.

Figure 15 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 2 for the 1:1 ratio mixed beam plan. The white crosshair indicates
the position of the planes shown. The PTV is displayed as in red colorwash
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3.3.2.2

IMRT/Mixed Beam
The IMRT (Figure 14) and the selected mixed beam isodose distributions (Figure 15 and Figure

16) showed less conformal PTV coverage than the HT but also displayed preferable features in the dose
distribution.

Figure 16 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 2 for the 1:4 ratio mixed beam plan. The white crosshair indicates
the position of the planes shown. The PTV is displayed as in red colorwash
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The IMRT plan, in contrast to the HT plan, had a small (less than 5%) cold spot near the center
of the PTV as seen the sagittal and coronal planes in Figure 14. The two selected mixed beam plans
displayed larger inhomogeneities in the PTV than the HT or IMRT plans (with this being more evident in
the 1:4 ratio mixed beam plan than the 1:1). For the 1:4 ratio mixed beam plan (Figure 16), a 5% hot spot
is visible on the inferior section of the ear and a 5% cold spot near the center of the PTV.
The IMRT and mixed beam plan isodose distributions exhibited a sharper distal fall off compared
to the HT plan and a lower dose near the eyes. Combining the electrons to the IMRT plan reduces the
volume of tissue receiving a dose greater than 25 Gy and greatly reduces the tissue receiving a dose
greater than 5 Gy. The 5 Gy isodose line can be seen encompassing the patient‟s cranium in the HT plan,
nearly encompassing in the IMRT plan, however, the mixed beam plans encompass a much smaller
volume of tissue.
3.3.3
3.3.3.1

DVH Comparisons
All mixed beam plans
DVH comparisons for the PTV and OARs for the mixed beam plans are shown in Figure 17 and

Figure 18, respectively. The mixed beam plans all showed similar PTV dose volume coverage with the
exception of the 0:1 ratio (electron only) plan, which was significantly larger volume receiving above and
below the desired prescription.
For the OARs, there was a strong correlation between the amount of electrons in the mixed beam
ratio and the OAR sparing. The 0:1 ratio plan gave the lowest max dose to the spinal cord and the lowest
mean dose to the contralateral parotid, followed by the 1:4 ratio mixed beam plan. With the exception of
the electron only plan, all mixed beam plans showed a similar dose-volume relationship for the ipsilateral
eye. The spinal cord was well below the optimization constraint set of 45 Gy, yet, the mixed plan plans
continually reduced the dose to the spinal cord as more electrons were introduced. A similar observation
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can be made with the contralateral parotid. Depending on the physician‟s preference to spare the OARs at
the expensive of PTV homogeneity both the 1:1 and 1:4 ratio plan give desirable DVH results.

Figure 17 DVHs for patient 2 for the PTV of the mixed beam plans.

3.3.3.2

Select mixed beams, HT, and IMRT
DVHs for the PTV and OARs for the HT, IMRT, and selected mixed beams (1:1 and 1:4 ratio)

are shown in Figure 19. The HT plan showed a smaller volume of PTV receiving greater than and less
than the prescription dose of 65.0 Gy compared to the IMRT and mixed beam plans (this is reflected in
the isodose distribution of Figure 13). The HT plan showed a more uniform dose distribution in the PTV.
For the OARs, the HT and IMRT plans had a similar maximum spinal cord dose. Introducing
electrons to the plans reduced the maximum spinal cord dose in the 1:1 ratio and even more so for the 1:4
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plan. The mixed beam plans had the contralateral parotid receive a lower mean dose than either the
IMRT or HT plan. Overall, the mixed beam plans maintained the excellent sparing of the contralateral
parotid that was exhibited in the electron only plan while at the same time restoring the PTV‟s DVH near
that of the HT plan.

Figure 18 DVHs for patient 2 for the OARs of the mixed beam plans.

3.3.4

Radiation Oncologist Review
A radiation oncologist evaluated the clinical acceptability of the HT, IMRT, and mixed beam

plans and found them to be clinically acceptable. A complete list of individual plan reviews can be found
in Appendix A. After reviewing the dose distributions and DVHs for all the plans, he was indifferent on
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how the HT plan compared to the mixed beam plan. The PTV coverage of the HT plan and the lower
contralateral parotid dose of the mixed beam plan was the reason for being indifferent.

Figure 19 DVHs for patient 2 for the PTV and OARs for the HT, 1:0 ratio (IMRT), 1:1 ratio and 1:4
ratio mixed beam plan
3.3.5
3.3.5.1

Dose Statistics for the PTV and TCP
All mixed beam plans
Table 13 gives the dose statistics for the PTV from the mixed beam plans. The TCP values were

high in all cases. The TCP model estimated nearly 100% tumor control for all the plans but the electrononly plan, which was 99.7% tumor control. CI was highest for 1:1 ratio plan (0.699) followed by the
IMRT plan with 0.063. There was a weak correlation between the electron involvement and CI, however,
the electron only plan greatly increases with the additional component of IMRT (going from 0.176 to
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0.591 in the 1:4 ratio). Dose homogeneity index was similar for all mixed beam plans (within ± 0.002 of
0.055). Overall, the mixed beam plans are similar in dose statistics for the PTV.

Table 13 Dose statistics for the PTV for mixed beam plans for patient 2
PTV – Patient 2
Plan
1:0
2:1
1:1
1:2
1:3
1:4
0:1

3.3.5.2

TCP (%)
100.0
100.0
100.0
100.0
100.0
100.0
99.7

CI
0.650
0.654
0.699
0.520
0.596
0.591
0.176

DHI
0.063
0.055
0.054
0.057
0.057
0.053
0.177

Dmax (Gy)
66.8
66.8
66.8
66.8
66.9
67.0
70.6

Dmin (Gy)
62.7
63.2
63.3
63.1
63.2
63.5
59.1

Select mixed beams, HT, and IMRT plans
Table 14 gives the dose statistics for the PTV from the HT, IMRT, and select mixed beam plans.

The TCP values were within ± 0.2% of 99.9% tumor control. The CI was highest for the HT plan (0.765)
compared to the mixed beam plans (0.699 and 0.591 for the 1:1 and 1:4, respectively). The DHI value
did not vary much between the two mixed beam plans (~0.053), however the DHI was significantly lower
for the HT plan (0.017). The HT plan showed a lower DHI value, indicating the HT plan was more
homogeneous over the PTV.

Table 14 Dose statistics for the PTV for the HT, IMRT, and select mixed beam plans
PTV- Patient 2
Plan
HT
1:0
1:1
1:4

TCP (%)
99.9
100.0
100.0
100.0

CI
0.765
0.650
0.699
0.591

DHI
0.017
0.063
0.054
0.053

Dmax (Gy)
66.0
66.8
66.8
67.0
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Dmin (Gy)
64.9
62.7
63.3
63.5

3.3.6

Dose Statistics of the OARs and NTCP

Table 15 Dose statistics for the OARs for the mixed beam plans for patient 2
Critical Structures – Patient 2
Spinal
Parotidcon

cord

Lenscon

optic optic
Eyecon Eye ips nervecon nerveips

Lensips

Plan Dmean NTCP(%) Dmax NTCP(%) Dmax NTCP(%) Dmax NTCP(%) Dmax Dmax Dmax Dmax
1:0

8.2

8.6

43.3

0.3

1.8

<0.1

2.2

<0.1

5.9

2.9

7.6

11.1

2:1

6.0

6.8

39.0

0.1

1.7

<0.1

2.1

<0.1

4.8

4.8

6.2

13.5

1:1

5.1

6.1

37.2

<0.1

1.8

<0.1

2.0

<0.1

3.8

5.0

4.7

13.7

1:2

4.0

5.3

36.1

<0.1

1.4

<0.1

2.0

<0.1

3.4

5.1

3.8

14.1

1:3

3.5

5.0

35.8

<0.1

1.4

<0.1

2.0

<0.1

2.9

5.6

3.0

14.0

1:4

3.1

4.8

35.6

<0.1

1.6

<0.1

2.1

<0.1

3.6

6.0

3.7

16.0

0:1

1.1

3.7

30.7

<0.1

0.5

<0.1

1.4

<0.1

0.9

5.7

1.6

14.6

Table 16 Dose statistics for the OARs for the HT, IMRT, and select mixed beam plans for patient 2
Critical Structures – Patient 2
Parotidcon

Spinal cord

Lenscon

Lensips

Eyecon Eye ips

Plan Dmean NTCP Dmax NTCP Dmax NTCP Dmax NTCP Dmax Dmax

Optic
nervecon

Optic
nerveips

Dmax

Dmax

HT

13.2

14.4 41.2

0.4

3.1

0.1

3.4

0.1

12.0 11.9

16.5

21.4

1:0

8.2

8.6

43.3

0.3

1.8

<0.1

2.2

<0.1

5.9

2.9

7.6

11.1

1:1

5.1

6.1

37.2

<0.1

1.8

<0.1

2.0

<0.1

3.8

5.0

4.7

13.7

1:4

3.1

4.8

35.6

<0.1

1.6

<0.1

2.1

<0.1

3.6

6.0

3.7

16.0

3.3.6.1

Contralateral parotid

3.3.6.1.1

All mixed beam plans

Table 15 gives the dose statistics for the contralateral parotid for the mixed beam plans. Mean
dose and NTCP of salivary flow reduction to less 25% at six weeks was computed. Mean dose values
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had a strong correlation with electron involvement and ranged from 8.2 Gy for the 1:0 (IMRT only) to 1.1
Gy for the 0:1 (electron only). The NTCP followed the same trend as the mean dose. Using the 1:1 ratio
of electrons and photons reduced the NTCP for the contralateral parotid gland by approximately 2.5%
from the IMRT only plan.
3.3.6.1.2

Select mixed beams (1:4, 1:1), HT, and IMRT plan

Table 16 gives the dose statistics for the contralateral parotid for the HT, IMRT, and select mixed
beam plans. Mean dose and NTCP of salivary flow reduction to less than 25% at six weeks was
computed. Mean dose values were 13.2 Gy for HT, 8.2 Gy for IMRT, 5.1 Gy for the 1:1 mixed beam
ratio, and 3.1 Gy for the 1:4 mixed beam ratio. The 1:4 ratio plan significantly reduced the mean dose to
the contralateral parotid gland by 10.1 Gy compared to the HT plan. This resulted in an improvement of
NTCP from 14.4% to 4.8%.
3.3.6.2

Spinal Cord

3.3.6.2.1

All mixed beam plans

Maximum dose and NTCP of necrosis/myelitis was computed. Maximum dose values ranged
from 43.3 Gy for the 1:0 ratio to 30.7 Gy for the 0:1 ratio. NTCP for necrosis/myelitis was highest for the
1:0 plan (0.3%) and lowest for the 0:1 ratio plan (<0.1%). A substantial reduction was seen between the
1:0 (maximum dose of 43.3 Gy) and the 2:1 ratio (maximum dose of 39.0 Gy).
3.3.6.2.2

Select mixed beam (1:4), HT, and IMRT plan

Maximum dose and NTCP of necrosis/myelitis was computed. Maximum dose values ranged
from 43.3 Gy for the IMRT plan to 35.6 Gy for the 1:4 ratio plan. The HT plan was 2.1 Gy lower in
maximum dose for the spinal cord than the IMRT but 5.9 Gy higher than the 1:4 ratio‟s maximum dose.
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The risk of spinal cord complication for the HT plan was 0.4 % for the HT plan compared to <0.1% for
the 1:1 and <0.1% for the 1:4 ratio. Using mixed beam plans reduced the NTCP for the spinal cord.
3.3.6.3

Eyes, lens, and optic nerves

3.3.6.3.1

All mixed beam plans

Table 15 gives the dose statistics for the eyes, lens, and optic nerves for the mixed beam plans.
Maximum dose was computed for these OARs along with NTCP of cataract requiring (surgical)
intervention. The maximum dose and NTCP values for the contralateral and ipsilateral lens were similar
with the electron only plan giving a slightly lower maximum dose to both the contralateral and ipsilateral
lens. For the eyes and the optic nerve, there was a general trend of the dose decreasing for the
contralateral OAR as electron involvement increased, however, the reverse was observed for the
ipsilateral OAR. Doses for these OARs had near zero NTCP values to induce blindness.
3.3.6.3.2

Select mixed beams, HT, and IMRT plan

Table 16 gives the dose statistics for the eyes, lens, and optic nerves for the HT, IMRT, and select
mixed beam plans. Maximum dose was computed for these OARs along with NTCP of cataract requiring
(surgical) intervention. The maximum dose for the lens, eyes, and optic nerves was higher in the HT
plan than IMRT or mixed beam plans. The NTCP values for the lens to develop a cataracts requiring
surgical intervention was higher in the HT plan, however, the NTCP value was still very small (0.081 for
the ipsilateral lens).
3.3.7

Non-specific Normal Tissue
The normal tissue volume receiving between 5 and 25 Gy for this patient was 4052 cm3 for the

HT plan, 3428 cm3 for the IMRT plan, and 1235 cm3 for the mixed beam plan. The difference in volume
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between the HT and the mixed beam plan was 2817 cm3. Normalizing the volumes to the HT plan, the
mixed beam plan gave 30% volume.
3.4

Patient Three - Parotid

3.4.1

Patient Specific Information
A 36 year old female was diagnosed to have high grade adenoidcystic carcinoma of the right

parotid gland, stage T2N0M0. She underwent a parotidectomy (positive margins) and was referred for
postoperative radiation therapy to treat the parotid bed and stylomastoid region. 63.9 Gy in 32 fractions
was delivered by IMRT.
3.4.2

Isodose Distributions
Isodose distributions for HT, IMRT (1:0), and a selected mixed beam plan (1:1 ratio) are

displayed in Figure 20-22. Dose statistics for the isodose distributions can be found in Table 18 and
Table 20. The white lines in the CT images indicate the position of the orthogonal planes and the purple
colorwash indicates the primary PTV. The red isodose line represents the desired prescription dose (63.9
Gy) to the primary PTV. PTV60 (teal colorwash) and PTV54 (yellow colorwash) are also displayed.
3.4.2.1

HT
The HT isodose distribution showed more conformal coverage in the primary PTV than the

IMRT and mixed beam plans. No hot spots over 5% were observed in the primary PTV for the HT plan.
Slight ~5% cold spots (purple isodose line) were located on the distal edge of the PTV along the occipital
bone and at the abutment region between the primary PTV and the secondary PTV60 (colorwashed as teal
in Figure 20). The HT plan showed a steep dose fall off to 45 Gy near the base of the brain and brainstem
compared to the IMRT and mixed beam plans. This resulted in lower dose to the posterior and inferior
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section of the brain. For the primary and secondary PTVs, the maximum target doses were noticeably
lower in the HT than the select mixed beam or IMRT plan.

Figure 20 Isodose dose distribution in transverse (a), sagittal (b), and coronal planes (c) through the
center of the primary PTV for patient 3 for TomoTherapy plan. The white crosshair indicates the
position of the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal;
PTV54, yellow.
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3.4.2.2

IMRT/Mixed Beam
The IMRT and select mixed beam isodose distributions showed few hot and cold spots. 5% hot

spots on the IMRT plan were located near the back of the neck on the primary PTV and posterior to the
ipsilateral ear for the select mixed beam plan.

Figure 21 Isodose dose distribution in transverse (a), sagittal (b), and coronal planes (c) through the
center of the primary PTV for patient 3 for IMRT (1:0) plan. The white crosshair indicates the
position of the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal;
PTV54, yellow.
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Similar to the HT plan, 5% cold spots appeared near the junction of the primary and secondary PTV and
also appeared near the near the region where the primary PTV abuts the brain.

Figure 22 Isodose dose distribution in transverse (a), sagittal (b), and coronal planes (c) through the
center of the primary PTV for patient 3 for the IMRT + electron (1:1) plan. The white crosshair
indicates the position of the planes shown. PTVs are shown in colorwash. Primary PTV, purple;
PTV60, teal; PTV54, yellow.
The dose gradient for both IMRT and mixed beam plans at the distal edges of the targets was not as sharp
as the HT plan. The green isodose line (45 Gy) shows the brain receiving more volume to a high dose.
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The distal fall off to the 45 Gy isodose line is less for the mixed beam plan than the IMRT only. This is
observable near the posterior region of the skull.
3.4.3
3.4.3.1

DVH Comparisons
All mixed beam plans
DVH comparisons for the PTV and OARs for the mixed beam plans are shown in Figure 23 and

Figure 24, respectively.

Figure 23 DVH for patient 3 for the PTV of the mixed beam plans
Note that the planning of the 0:1 electron only mixed beam plan was not performed for this patient
because of the multiple PTV required abutting electron fields rather than a single enface electron beam.
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The mixed beam plans all showed similar PTV dose volume coverage. Varying the electron involvement
in the mixed beam plan did not contribute much changing the PTV coverage.

Figure 24 DVH for patient 3 for the OARs of the mixed beam plans
For the OARs, there was a general trend that the increasing the electron involvement reduced the
mean dose for the contralateral parotid. This did not appear to be the case for the maximum dose to the
spinal cord for which there was little correlation between. The volume of the brain receiving over 50 Gy
was similar for the mixed beam plan, however separation between the plans appears between brain
volume receiving 5 Gy and 40 Gy.
3.4.3.2

Select mixed beam, HT, and IMRT
DVHs for the PTVs for the HT, IMRT, and selected mixed beam (1:1 ratio) are shown in Figure

25 .
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Figure 25 DVH for patient 3 for the PTV of the HT, IMRT, and selected mixed beam plan

The HT plan showed better dose homogeneity in the three PTVs. The mixed beam and IMRT plan
showed small volumes of the PTV receiving lower than prescription dose which was created by the
abutment of the PTVs and also the close proximity of the primary PTV to the spinal cord. The HT plan
also showed the secondary PTVs receiving a smaller volume of dose pass the maximum prescription the
respective PTV.
DVHs for the OARs for the HT, IMRT, and selected mixed beam are shown in Figure 26. The
HT plan showed the lowest maximum spinal cord dose, along with the lowest volume of brain tissue
receiving over 50 Gy. The IMRT and mixed beam plan gave similar volume of brain over 50 Gy. The
mixed beam plan gave the lowest mean dose to the contralateral parotid.
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Figure 26 DVH for patient 3 for the OARs of the mixed beam plan
3.4.4

Radiation Oncologist Review
A radiation oncologist evaluated the clinical acceptability of the HT, IMRT, and mixed beam

plans and found the HT plan to be marginally acceptable and was indifferent about the IMRT plan and the
best mixed beam ratio. A complete list of individual plan reviews can be found in Appendix A. After
reviewing the dose distributions and DVHs for all the plans, he ranked the HT plan superior to the mixed
beam plan. Significant improvements in the PTVs coverage was listed as a reason for preferring HT plan
over the mixed beam. The radiation oncologist suggested that the higher maximum dose to the spinal
cord may be of concern.
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3.4.5
3.4.5.1

Dose Statistics of the PTVs and TCP
All mixed beam plans
Table 17 gives the dose statistics for the PTV for the mixed beam plans. The TCP value for the

primary PTV ranged from 99.0% for the 1:1 ratio plan to 97.7% for the 1:3 ratio plan. There did not
appear too much correlation with heavier electron weighting and primary PTV‟s TCP. However, for the
secondary PTVs, the IMRT plan gave higher TCP values and the TCP generally decreased with more
electron involvement. CI was highest for the IMRT plan for all three PTVs. DHI was similar for all
mixed beam plans, expect for the IMRT plan which had higher DHI values on the primary PTV and
PTV54.

Table 17 Dose statistics for the PTV for the mixed beam plans for patient 3
PTV – Patient 3
Patient 3
PTV 63.9

PTV 60

PTV 54

Plan
1:0
2:1
1:1
1:2
1:3
1:4
1:0
2:1
1:1
1:2
1:3
1:4
1:0
2:1
1:1
1:2
1:3
1:4

TCP (%)
98.7
98.9
99.0
98.8
97.7
98.1
99.1
98.6
98.6
98.4
98.2
98.1
92.7
88.9
89.0
88.9
89.8
89.1

CI
0.517
0.400
0.412
0.417
0.413
0.412
0.257
0.197
0.200
0.184
0.190
0.203
0.094
0.047
0.052
0.063
0.063
0.066

DHI
0.186
0.158
0.166
0.162
0.176
0.171
0.117
0.128
0.128
0.147
0.159
0.158
0.112
0.097
0.126
0.124
0.108
0.120
63

Dmax (Gy)
67.4
66.3
67.0
66.9
66.9
66.7
64.5
63.4
63.3
63.9
64.0
63.7
58.5
56.7
57.5
57.0
57.2
57.1

Dmin (Gy)
55.5
56.2
56.4
56.5
55.7
55.8
57.4
55.7
55.6
55.0
54.4
54.3
52.5
51.5
50.7
50.3
51.3
50.6

Table 18 Dose statistics for the PTV for the HT, IMRT, and select mixed beam plan
PTV – Patient 3
patient 3
Plan
PTV 63.9
HT
1:0
1:1
PTV 60
HT
1:0
1:1
PTV 54
HT
1:0
1:1

3.4.5.2

TCP (%) CI
98.8
0.533
98.7
0.517
98.9
0.412
97.9
0.166
99.1
0.257
98.6
0.200
89.2
0.068
92.7
0.094
89.0
0.052

DHI
0.081
0.186
0.166
0.091
0.117
0.128
0.071
0.112
0.126

Dmax (Gy)
65.1
67.4
67.0
61.6
64.5
63.3
55.8
58.5
57.5

Dmin (Gy)
59.9
55.5
56.4
56.2
57.4
55.6
52.0
52.5
50.7

Select mixed beam, HT, and IMRT plans
Table 18 gives the dose statistics for the PTV from the HT, IMRT, and select mixed beam plan

(1:1 ratio). TCP values for the primary PTV were similar with ± 0.2% of 98.8%. For the secondary
PTVs, the IMRT plan resulted in the highest TCP. This higher TCP could be due to the high maximum
dose of the IMRT plan. CI was highest for the HT plan (0.533) for the primary PTV. For the secondary
PTVs, the IMRT only plan gave the highest CI values (PTV60=0.257 and PTV54=0.094).

The HT plan

showed the lowest DHI values, indicating that the HT plan was more homogeneous over the three PTVs.
3.4.6

Dose Statistics of the OARs and NTCPs

3.4.6.1

Contralateral parotid

3.4.6.1.1

All mixed beam plans

Table 19 gives the dose statistics for the contralateral parotid for the mixed beam plans. Mean
dose and NTCP of salivary flow reduction to less than 25% at six weeks was computed. Mean dose
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values ranged from 11.2 Gy for the 1:3 ratio plan to 13.2 Gy for the 2:1 ratio plan. This corresponded to
NTCP values ranging from 11.8% to 14.3% for the 1:3 and 2:1, respectively.
3.4.6.1.2

Select mixed beam (1:1), HT, and IMRT plan

Table 20 gives the dose statistics for the contralateral parotid for the HT, IMRT, and select mixed
beam plans. Mean dose was slightly higher for the HT plan (13.9 Gy) compared to the IMRT (12.6 Gy)
and mixed beam plan (12.1 Gy). The NTCP values were as following: HT=15.4, IMRT=13.6 and 1:1
ratio=13.0.
3.4.6.2

Spinal Cord

3.4.6.2.1

All mixed beam plans

Maximum dose and NTCP of necrosis/myelitis was computed. The close proximity of the PTVs
to the spinal cord resulted in larger than typically acceptable (45 Gy at our clinic) maximum spinal cord
doses. The maximum spinal cord dose for the IMRT, 2:1, and 1:2 plan were slightly over the 45 Gy
mark, with the largest being the 2:1 ratio (46.5 Gy). However comparing the NTCP values for the plans,
the IMRT had the highest value at approximately 1% complication risk.
3.4.6.2.2

Select mixed beam (1:1), HT, and IMRT plan

Again the close proximity of the PTVs to the spinal cord resulted in larger than typically
acceptable (45 Gy at our clinic) maximum spinal cord doses for the IMRT plan. Introducing a 1:1 ratio of
electrons reduced the maximum spinal cord dose to 44.3 Gy. The lowest maximum spinal cord dose was
the HT plan (41.3 Gy). However comparing the NTCP values for the plans, the IMRT had the highest
value at approximately 1% complication risk.
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3.4.6.3

Brain

3.4.6.3.1

All mixed beam plans

Maximum dose and NTCP of necrosis was computed for the brain. The heavier weighed electron
ratio plans gave a higher maximum dose to the brain (69.3), however this was a small volume receiving
the higher dose and NTCP values did not reflected the maximum dose trend. The highest NTCP value for
the brain was the IMRT plan (0.1%) while the lowest value was the 1:3 ratio at (<0.1%).
3.4.6.3.2

Select mixed beam, HT, and IMRT plan

Maximum dose and NTCP of necrosis was computed for the brain. The IMRT and mixed beam
plan has similar maximum dose values of about 67 Gy, however the IMRT plan showed an increase risk
of complication (0.1 % for IMRT compared to <0.1% for the 1:1 ratio). The HT plan had a similar low
risk of complication for the brain at about <0.1%.
3.4.6.4

Lens, eyes, optic chiasm, and optic nerve

3.4.6.4.1

All mixed beam plans

Maximum dose was computed for the lens, eyes, optic chiasm, and optic nerve along with NTCP
values for cataracts requiring (surgical) intervention. The maximum dose and NTCP values for the
contralateral lens increased with electron involvement in the ratio, going from 3.9 Gy with a 0.1% risk of
complication for the IMRT plan to 5.4 Gy with a 0.3% risk for the 1:4 ratio plan. For the ipsilateral lens,
the converse was true, and the IMRT gave the highest dose (7.0 Gy) and highest NTCP value (0.8).
Below 1:2 ratio there was not much change in maximum dose for ipsilateral eye. The maximum dose for
the eyes followed the same trend as the lens, with IMRT being the lowest contralateral maximum dose
(6.3 Gy) and the highest ipsilateral dose (13.0 Gy). The maximum dose to the optic chiasm ranged from
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45.6 Gy for the 1:1 ratio plan to 48.9 Gy for the 1:4 ratio plan. For the ipsilateral optic nerve, the
maximum dose was 39.9 Gy for the 1:4 ratio and 32.7 Gy for the IMRT plan.
3.4.6.4.2

Select mixed beam, HT, and IMRT plan

Maximum dose to the lens and eyes was higher in the HT plan than the IMRT or select mixed
beam plan. However, NTCP values were only slightly increased for the contralateral lens (0.6%
compared to 0.1% for IMRT) and actually decreased for the ipsilateral lens (0.5% compared to 0.8% for
IMRT). This is due to only a small volume being irradiated to the maximum dose. The maximum dose
for the optic chiasm was lowest for the HT plan (36.6 Gy) and the maximum dose to the optic nerve was
comparable to the other plans (33.4 Gy for HT).

Table 19 Dose statistics for the OARs for the mixed beam plans for patient 3
Critical Structures – Patient 3
Parotidcon

Spinal cord

Lenscon

Lensips

Brain

Plan Dmean NTCP Dmax NTCP Dmax NTCP Dmax NTCP Dmax NTCP
1:0 12.6 13.6 46.2 1.0 3.9 0.1 7.0 0.8 67.0 0.1
2:1 13.2 14.3 46.5 0.9 4.1 0.1 6.1 0.5 66.8 0.1
1:1 12.1 13.0 44.3 0.6 4.6 0.2 6.0 0.4 67.1 0.1
1:2 11.5 12.1 46.0 0.9 4.9 0.2 5.6 0.4 68.4 0.1
1:3 11.2 11.8 44.4 0.6 5.2 0.3 5.7 0.4 68.1 <0.1
1:4 11.3 12.0 45.2 0.7 5.4 0.3 5.7 0.4 69.3 0.1

3.4.7

Optic Optic
Eyecon Eye ips chiasm nerveips

6.3
6.7
7.7
8.2
8.6
9.0

Dmax
13.0 47.6
10.7 48.6
10.3 45.6
10.1 47.9
10.2 47.3
10.3 48.9

32.7
34.0
35.4
37.2
34.8
39.9

Non-specific Normal Tissue
The normal tissue volume receiving between 5 and 25 Gy for this patient was 3004 cm3 for the

HT plan, 2285 cm3 for the IMRT plan, and 2640 cm3 for the mixed beam plan. The difference in volume
between the HT and the mixed beam plan was 364 cm3. Normalizing the volumes to the HT plan, the
mixed beam plan gave 88% volume.
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Table 20 Dose statistics for the OARs for the HT, IMRT, and select mixed beam for patient 3
Critical Structures – Patient 3
Parotidcon

Spinal cord

Lenscon

Lensips

Brain

Eyecon Eye ips

Optic Optic
chiasm nerveips

Plan Dmean NTCP Dmax NTCP Dmax NTCP Dmax NTCP Dmax NTCP
Dmax
HT 13.9 15.4 41.3 0.5 7.6 0.6 7.4 0.5 65.2 <0.1 18.3 25.4 36.6
1:0 12.6 13.6 46.2 1.0 3.9 0.1 7.0 0.8 67.0 0.1 6.3 13.0 47.6
1:1 12.1 13.0 44.3 0.6 4.6 0.2 6.0 0.4 67.1 <0.1 7.7 10.3 45.6

3.5

33.4
32.7
35.4

Patient Four – Nasal Cavity

3.5.1

Patient Specific Information
A 73 year old male was diagnosed to have moderately differentiated squamous cell carcinoma in

the left nasal cavity, stage T1-2N0M0. Radiation was used as a definitive treatment of his lesion. He
received 70 Gy at 2 Gy per fraction with IMRT.
3.5.2

Isodose Distributions
Isodose distributions for HT, IMRT, and the selected mixed beam plan (1:3 ratio) are displayed in

Figure 27-29. Dose statistics for the isodose distributions can be found in Table 22 for the PTV and
Table 24 for the critical structures. The white lines in the CT images indicate the position of the
orthogonal planes and the red colorwash indicates the primary PTV. The red isodose line represents the
desired prescription dose (70.0 Gy) to the PTV.
3.5.2.1

HT
The HT isodose distribution showed a conformal coverage with fewer cold spots than the IMRT

and mixed beam plans for the PTV. Hot spots in the HT plan were small (~5%) and were generally
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located along the surface of the nose. These 5% hotspots (73.5 Gy) observable in the yellow isodose line
can be seen in Figure 27.

Figure 27 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 4 for the TomoTherapy plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as in red colorwash.
No cold spots greater than 5% were noted in the PTV for the HT plan. The HT plan showed a steep dose
fall off on distal edge of the PTV. For the HT plan, a significant volume of tissue outside the PTV
received low dose (5 Gy or more) compared to the mixed beam plan.
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3.5.2.2

IMRT/Mixed Beam
The IMRT and the select mixed beam plan isodose distributions showed less conformal PTV

coverage, slower high dose fall off at the distal PTV edge, but lower volumes of tissue receiving over 5
Gy.

Figure 28 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 4 for the IMRT (1:0) plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as in red colorwash.
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5% hotspots appear in the IMRT along the posterior edge of the PTV and along the bridge of the nose.
This can be seen in the sagittal slice in Figure 28. The mixed beam plan is slightly less conformal than
the IMRT plan. Larger volumes of PTV had 5% hotspots that were located near the center of the PTV,
which is possibly due to electron scatter in the nasal passages.

Figure 29 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 4 for the IMRT + electron (1:3) plan. The white crosshair
indicates the position of the planes shown. The PTV is displayed as in red colorwash.
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The dose fall off to 45 Gy (the green isodose line) is faster in the HT plan and falls off distally before the
sphenoid bone as where 45 Gy isodose line just touches the sphenoid bone in the mixed beam and IMRT
plan, as seen in the sagittal slices. The amount of tissue receiving over 5 Gy is noticeably less in the
mixed beam plan compared to the HT plan and IMRT plan.
3.5.3
3.5.3.1

DVH Comparisons
All mixed beam plans
DVH comparisons for the PTV and OARs for the mixed beam plans are shown in Figure 30 and

Figure 31, respectively. The mixed beam plans all showed similar PTV does volume coverage with the
exception of the 0:1 ratio (electron only) plan, which was significantly less conformal.

Figure 30 DVH for patient 4 for the PTV of the mixed beam plans
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For the OARs displayed in Figure 31, the 0:1 ratio (electron only) plan gave the lowest maximum
and mean doses to the OARs. The 1:3 and 1:4 ratio plan show a smaller volume receiving both high and
low doses for the left lens and left eye than the other mixed beam plans. The 2:1 ratio plan gives a
smaller volume to high doses for the left optic nerve than the other mixed beam plans, however, all the
plans gave clinically acceptable maximum dose for the optic nerves.

Figure 31 DVH for patient 4 for the OARs of the mixed beam plans
3.5.3.2

Select mixed beam, HT, and IMRT
DVHs for the PTV and OARs for the HT, IMRT, and selected mixed beam (1:3 ratio) are shown

in Figure 32. The HT plan showed a lower volume of dose receiving over the prescription dose than the
IMRT or mixed beam plan while having a similar minimum dose. The mixed beam plan gave the lowest
maximum left eye and left lens dose.
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3.5.4

Radiation Oncologist Review
A radiation oncologist evaluated the clinical acceptability of the HT, IMRT, and the mixed beam

plans and found the plans to be marginally acceptable. A complete list of individual plan reviews can be
found in Appendix A.

Figure 32 DVH for patient 4 for the PTV and OARs for the HT, IMRT, and select mixed beam plans

After reviewing the dose distributions and DVHs for all the plans, he was indifferent on how the HT plan
compared to the mixed beam plan. No comment was provided on his decision. The radiation oncologist
did suggest that if nodal involvement had occurred, treating with the mixed beam fields would become
more complicated and he disliked having to treat patients with multiple modalities.
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3.5.5
3.5.5.1

Dose Statistics for the PTV and TCP
All mixed beam plans
Table 21 gives the dose statistics for the PTV for the mixed beam plans. The high TCP values

were recorded in all plans, statistically 100%. Conformity index (CI) was highest for the 1:1 ratio plan
(0.852). CI trended down passed the 1:1 ratio. DHI was largest for the electron only plan at 0.290 which
was improved to 0.089 by the addition of electrons in the 2:1 ratio plan. This was only a slight from the
IMRT only plan‟s conformity of 0.086.

Table 21 Dose statistics for the PTV for the mixed beam plans for patient 4
PTV – Patient 4
Plan
1:0
2:1
1:1
1:2
1:3
1:4
0:1

TCP (%)
100.0
100.0
100.0
100.0
100.0
100.0
99.9

CI
0.755
0.842
0.852
0.846
0.826
0.824
0.746

DHI
0.086
0.089
0.095
0.113
0.093
0.097
0.290

Dmax (Gy)
74.7
74.8
75.1
75.6
75.4
75.5
80.5

Dmin (Gy)
68.7
68.6
68.5
67.7
68.9
68.7
60.2

Table 22 Dose statistics for the PTV for the HT, IMRT, and select mixed beam plan for patient 4
PTV – Patient 4
Plan
HT
1:0
1:3

TCP (%)
100.0
100.00
100.0

CI
0.798
0.755
0.826

DHI
0.074
0.086
0.093

Dmax (Gy)
73.9
74.7
75.4
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Dmin (Gy)
68.7
68.7
68.9

3.5.5.2

Select mixed beam, HT, and IMRT plans
Table 22 gives the dose statistics for the PTV for the HT, IMRT and select mixed beam plan.

Similar to the mixed beam plans, the patient had high TCP values for all three cases. This is most likely
due to the higher dose required to control the infiltrating moderately differentiated cancer. CI was highest
for the 1:3 ratio plan (0.826) but closely followed by the HT plan (0.798). DHI was the best for the HT
(0.074) and degraded to 0.093 for mixed beam.
3.5.6

Dose Statistics of the OARs and NTCPs
Table 23 and Table 24 display the related dose statistics for the OARs and NTCPs for patient 4.

3.5.6.1
3.5.6.1.1

Lens
All mixed beam plans

Table 23 Dose statistics for the OARs for the mixed beam plans for patient 4
Critical Structures – Patient 4

Left lens

Right lens

Left eye

Right eye

Right
optic
nerve

Left
optic
nerve

Plan Dmax NTCP(%) Dmax NTCP(%) Dmax NTCP(%) Dmax NTCP(%) Dmax Dmax
1:0 8.9
0.6
9.9
0.6
36.0
<0.1
39.2
<0.1
36.6
32.7
2:1 11.0
2.2
9.6
0.8
32.1
<0.1
33.2
<0.1
30.1
25.1
1:1 10.6
2.6
9.8
0.9
32.3
<0.1
33.8
<0.1
30.0
24.0
1:2 8.8
0.6
8.0
0.4
27.5
<0.1
32.3
<0.1
27.7
22.5
1:3 6.6
0.3
8.5
0.4
28.4
<0.1
33.5
<0.1
27.8
25.0
1:4 7.6
0.6
9.2
0.5
30.2
<0.1
33.0
<0.1
26.8
25.4
0:1 4.3
0.1
7.8
0.2
22.7
<0.1
30.0
<0.1
23.0
19.5
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Maximum dose and NTCP for cataract requiring (surgical) intervention was computed for the
lens. The electron only had both the lowest left and right lens maximum dose (4.3 Gy and 7.8 Gy
respectively) along with the lowest NTCP value (0.1 and 0.2 respectively). The maximum doses for the
lens for the IMRT plan was reduced (8.9 Gy and 9.9 Gy, respectively) to (6.6 Gy and 8.5 Gy) by the 1:3
ratio mixed beam plan.
3.5.6.1.2

Select mixed beam (1:3), HT, and IMRT plan

The mixed beam plan gave a lower maximum dose to the lens than the HT or IMRT plan did.
This corresponded to about a 2% lower NTCP for the right lens than the HT plan, however the left lens
was actually slightly lower for the HT plan than the mixed beam plan despite the higher maximum lens
dose.
3.5.6.2

Eye and optic nerve

3.5.6.2.1

All mixed beam plans

Maximum dose to the eyes was highest for the HT plan (left eye-36 Gy and right eye-39.2 Gy)
and also for the optic nerve (however the dose was clinically acceptable). The lowest dose for the eyes
and optic nerve was the electron only plan. Incorporating the IMRT into the electron only plan for the
optic eyes raised the maximum dose from 22.7 Gy and 30.0 Gy to 28.4 Gy and 33.5 Gy, respectively
(compared to IMRT 36.0 Gy and 39.2 Gy).
3.5.6.2.2

Select mixed beam, HT, and IMRT plan

Maximum dose was computed for both the eyes and optic nerves, along with the NTCP for
blindness for the lens. Similar to the results with the lens, the mixed beam plan saw a significant decrease
in maximum eye dose compared to the HT or the IMRT plan. The risk for complication was low in all
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three plans. Again the mixed beam plan resulted in a lower maximum dose for the optic nerve than the
IMRT or HT plan.

Table 24 Dose statistics for the OARs for the HT, IMRT, and select mixed beam plan for patient 4
Critical Structures – Patient 4

Left lens

Right lens

Left eye

Right eye

Right
optic
nerve

Left
optic
nerve

Plan Dmax NTCP(%) Dmax NTCP(%) Dmax NTCP(%) Dmax NTCP(%) Dmax Dmax
HT 8.0
0.3
14.9
2.8
40.5
<0.1
37.6
<0.1
30.6
33.4
1:0 8.9
0.6
9.9
0.6
36.0
<0.1
39.2
<0.1
36.6
32.7
1:3 6.6
0.3
8.5
0.4
28.4
<0.1
33.5
<0.1
27.8
25.0

3.5.7

Non-specific Normal Tissue
The normal tissue volume receiving between 5 and 25 Gy for this patient was 1863 cm3 for the

HT plan, 1256 cm3 for the IMRT plan, and 728 cm3 for the mixed beam plan. The difference in volume
between the HT and the mixed beam plan was 1135 cm3. Normalizing the volumes to the HT plan, the
mixed beam plan gave 39% volume.
3.6
3.6.1

Patient Five – Nasal Cavity
Patient Specific Information
A 90 year old female was diagnosed to have squamous cell carcinoma of the left nasal septum,

cT1N0M0. She underwent primary radiotherapy for her nasal cancer at a dose of 63 Gy in 28 fractions
using a mix of 6 MV photons and 12 MeV electrons while the patient had a Cerrobend mask with custom
bolus nose plugs.
3.6.2

Isodose Distributions
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Isodose distributions for HT, IMRT (1:0), and a selected mixed beam plan (1:4 ratio) are
displayed in Figure 33-35. Dose statistics for the isodose distributions can be found in Table 26 for the
PTV and Table 28 for the critical structures. The white lines in the CT images indicate the position of the
orthogonal planes and the red colorwash indicates the primary PTV. The red isodose line represents the
desired prescription dose (65.0 Gy) to the PTV.
3.6.2.1

HT

Figure 33 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 5 for the TomoTherapy plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as in red colorwash.
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The HT isodose distribution showed more conformal coverage than the IMRT and mixed beam
plans. No hot or cold spots greater than 5% were observed in the PTV for the HT plan. The HT plan
showed a steep lateral dose fall off to 35 Gy from the PTV compared to the IMRT only plan.

Figure 34 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 5 for the IMRT (1:0) plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as in red colorwash.
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The HT plan showed a steep distal dose fall off to 45 Gy from the PTV compared to the mixed beam plan.
The HT plan showed a larger area of tissue outside the PTV receiving a dose greater than 5 Gy than
compared to the mixed beam plan.
3.6.2.2

IMRT/Mixed Beam

Figure 35 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV for patient 5 for the IMRT + electron (1:4) plan. The white crosshair
indicates the position of the planes shown. The PTV is displayed as in red colorwash.
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The IMRT and selected mixed beam isodose distributions showed light 5% hot and cold spots. In
the IMRT plan, the distal edge of the PTV has the 5% cold spot, purple isodose line (61.75 Gy), breaches
the PTV.

For the mixed beam plan, there is a 5% cold spot near the orbit of the left eye. Both the IMRT

and mixed beam plan show a small hot spot near the superior-posterior region of the PTV. The IMRT
and mixed beam plan isodose distributions exhibited similar fall off distal to the PTV, but the mixed
beam plan showed a sharper fall lateral to the beam‟s edge.
3.6.3
3.6.3.1

DVH Comparisons
All mixed beam plans
DVH comparisons for the PTV and OARs for the mixed beam plans are shown in Figure 36 and

Figure 37, respectively.

Figure 36 DVH for patient 5 for the PTV of the mixed beam plans
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The mixed beam plans all showed similar PTV dose volume coverage with the exception of the 0:1 ratio
(electron only) plan, which was significantly less conformal and had a higher maximum dose to the PTV.
For the OARs, the 0:1 ratio plan gave the lowest mean and max dose eyes and lens, followed by
the 1:4 and 2:1 ratio mixed beam plan. There did not appear to be a strong correlation between the
electron involvement maximum doses for the mixed beam plan.
3.6.3.2

Select mixed beam, HT, and IMRT

Figure 37 DVH for patient 5 for the OARs of the mixed beam plans
DVHs for the PTV and OARs for the HT, IMRT, and selected mixed beam (1:4 ratio) are shown
in Figure 38. The HT plan showed a smaller volume of the PTV receiving greater than and less the
prescription dose of 65 Gy compared to the IMRT and mixed beam plan. It should be noted that the
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mixed beam plan appears to give a more uniform dose than the IMRT plan, however less uniform than the
HT plan.
For the OARs, the lens dose among the plans was similar. The left eye shows a higher yet still
clinically acceptable maximum dose for the IMRT plan. The HT plan gives a lower maximum dose to the
left eye than the select mixed beam plan.

Figure 38 DVH for patient 5 for the PTV and OARs for the HT, IMRT, select mixed beam plans
3.6.4

Radiation Oncologist Review
A radiation oncologist evaluated the clinical acceptability of the HT, IMRT, and mixed beam

plans and found the HT plan to be marginally acceptable, indifferent about the IMRT plan, and found the
best mixed beam ratio to be acceptable. A complete list of individual plan reviews can be found in
Appendix A. After reviewing the dose distributions and DVHs for all the plans, he ranked the
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TomoTherapy plan marginally inferior to the mixed beam plan. Being able to shield the eye was listed as
a reason for preferring mixed beam plan over the HT plan. The radiation oncologist suggested that he felt
more confident treating around the lens with lead shielding in place.
3.6.5

Dose Statistics for the PTV and TCP

3.6.5.1

All mixed beam plans
Table 25 gives the dose statistics for the PTV for the mixed beam plans. The TCP values were

comparable (within ± 0.1% of 100.0% tumor control) for all the plans. Conformity index (CI) was
highest for the 0:1 ratio plan (0.573) followed closely by the 1:3 plan with 0.436. Dose homogeneity
index varied among the plan and was best for the 2:1 ratio plan (DHI=0.071) and ranged to the worst
value of 0.191 for the 0:1 ratio plan.

Table 25 Dose statistics for the PTV for the mixed beam plans for patient 5
PTV – Patient 5
Patient 5

3.6.5.2

Plan
1:0
2:1
1:1
1:2
1:3
1:4
0:1

TCP (%)
100.0
100.0
100.0
100.0
100.0
100.0
100.0

CI
0.413
0.333
0.397
0.374
0.436
0.404
0.573

DHI
0.138
0.071
0.078
0.083
0.096
0.090
0.191

Dmax (Gy)
67.9
66.3
66.6
67.0
67.0
67.1
73.6

Dmin (Gy)
58.9
61.7
61.5
61.5
60.7
61.3
61.2

Select mixed beam (1:4), HT, and IMRT plans
Table 26 gives the dose statistics for the PTV from the HT, IMRT, and select mixed beam plans.

The TCP values were within ± 0.1% of 100.0% tumor control.
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Table 26 Dose statistics for the PTV for the HT, IMRT, and select mixed beam plan for patient 5
PTV – Patient 5
Patient 5

Plan
HT
1:0
1:4

TCP (%)
100.0
100.0
100.0

CI
0.797
0.413
0.404

DHI
0.039
0.138
0.090

Dmax (Gy)
66.1
67.9
67.1

Dmin (Gy)
63.5
58.9
61.3

The CI for the IMRT plan and the mixed beam plan were similar (IMRT=0.413 and 1:4 ratio=0.404).
The HT plan however had a much higher CI of 0.797. The HT plan showed a lower DHI value than the
mixed beam or the IMRT plan, indicating the HT plan was more homogeneous over the PTV.
3.6.6

Dose Statistics of the OARs and NTCPs

3.6.6.1

Lens and Eyes

3.6.6.1.1

All mixed beam plans

Table 27 gives the dose statistics for the lens and eyes for the mixed beam plans. Maximum dose
was calculated, along with the NTCP of cataract requiring (surgical) intervention for the lens and NTCP
of blindness for the eyes.

Table 27 Dose statistics for the OARs for the mixed beam plans for patient 5
Critical Structures – Patient 5
Left lens
patient 5 Plan
1:0
2:1
1:1
1:2
1:3
1:4
0:1

Dmax
3.5
2.8
3.3
3.3
3.6
2.7
1.8

NTCP(%)
0.1
0.1
0.1
0.1
0.1
0.1
<0.1

Right lens
Dmax
4.0
4.0
4.4
3.9
3.9
3.7
2.3

NTCP(%)
0.1
0.1
0.1
0.1
0.1
0.1
<0.1
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Left eye
Dmax
22.0
12.3
12.7
12.0
10.1
10.6
17.1

NTCP(%)
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Right eye
Dmax
9.1
9.1
8.7
10.1
7.8
9.7
8.4

NTCP(%)
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

As seen in the DVHs, the 1:4 and 0:1 gave the lowest maximum dose to the lens (2.7 Gy and 1.8 Gy for
the left lens and 3.7 Gy and 2.3 Gy for the right lens, respectively). Compared to the IMRT plan at 3.5
Gy for the left and 4.0 Gy for the right, the mixed beam plan slightly reduced the lens dose. NTCP were
overall low for both the lens and eyes for both plans (below 0.1%).
3.6.6.1.2

Select mixed beam plan, HT, and IMRT plan

Table 28 gives the dose statistics for the lens and eyes for the HT, IMRT, and select mixed beam
plans. Maximum dose was calculated, along with the NTCP of cataract requiring (surgical) intervention
for the lens and NTCP of blindness for the eyes. The mixed beam plan gave the lowest NTCP values for
the left and right lens (<0.1and 0.1, respectively) but HT had the lowest maximum right lens dose and a
comparable left lens dose to the mixed beam plan. The IMRT plan had a higher maximum dose for both
the lens and left eye. Overall, the HT plan was able to provide a plan with the best DHI while giving low
dose to the OARs.

Table 28 Dose statistics for the OARs for the HT, IMRT, and select mixed beam plan for patient 5
Critical Structures – Patient 5
Left lens
patient 5 Plan
HT
1:0
1:4

3.6.7

Dmax
2.9
3.5
2.7

Right lens
NTCP(%) Dmax
0.1
3.5
0.1
4.0
<0.1
3.7

Left eye
NTCP(%) Dmax
0.1
6.4
0.1
22.0
0.1
10.6

Right eye
NTCP(%) Dmax
<0.1
8.6
<0.1
9.1
<0.1
9.7

NTCP(%)
<0.1
<0.1
<0.1

Non-specific Normal Tissue
The normal tissue volume receiving between 5 and 25 Gy for this patient was 1152 cm3 for the

HT plan, 721 cm3 for the IMRT plan, and 515cm3 for the mixed beam plan. The difference in volume
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between the HT and the mixed beam plan was 627 cm3. Normalizing the volumes to the HT plan, the
mixed beam plan gave 45% volume.
3.7

Summary: Tables of Review
Table 29 shows the summary of the radiation oncologist review of the treatment plans for HT and

mixed beam.

Table 29 Summary of the radiation oncologist plan review
Patient

Plan acceptable?

Preferred
modality

Reason for choice of HT or Mixed
Beam

HT

Mixed Beam

1

Acceptable

Marginally
acceptable

HT

Better PTV coverage and less dose to
critical structure near the PTV for HT

2

Acceptable

Acceptable

Indifferent

HT better PTV coverage but more dose
to distal critical structures

3

Marginally
acceptable

Indifferent

HT

Significant improvement in dose
uniformity in PTV for HT

4

Marginally
acceptable

Marginally
acceptable

Indifferent

5

Marginally
acceptable

Acceptable

Mixed Beam

Disliked the use of more than one
modality (treating nodal spread) in
mixed beam
Preferred the ability to shield the eyes
for mixed beam

The HT plans were generally found to be better because of coverage and improvements in dose
uniformity in the PTV as seen in patient 1 and 3.
The mixed beam plans were generally found to be comparable or better to HT plans because of
distal organ sparing (e.g. contralateral parotid) and that the physician trusted and preferred the eye
shielding.
Table 30 shows a summary of the dose homogeneity index for the HT and mixed plan beam plan
and the difference between them.
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Table 30 Summary of the dose homogeneity index for the HT and mixed beam plan
DHI summary
Modality

DHI

HT

0.063

Mixed Beam

0.089

HT

0.017

Mixed Beam

0.054

HT

0.081

Mixed Beam

0.186

HT

0.074

Mixed Beam

0.093

HT

0.039

Mixed Beam

0.090

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

DHI difference

0.026

0.037

0.105

0.019

0.051

The DHI was lower for HT in all five patients. The largest difference between the DHIs occurred
for patient 3 and the smallest difference for patient 4.

Table 31 Summary of the normal tissue volumes receiving between 25 Gy and 5 Gy
Volume between 25 Gy and 5 Gy isodose
Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Modality

Volume in cc

Normalized to HT

HT

1129

100%

Mixed

1182

104%

HT

4051

100%

Mixed

1235

31%

HT

3003

100%

Mixed

2639

87%

HT

1863

100%

Mixed

728

39%

HT

1152

100%

Mixed

515

45%
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Table 31 shows a summary of the volume of normal tissue receiving between 25 Gy and 5 Gy.
Volumes are shown in cc and then normalized to HT‟s volume. For all but patient 1, the HT plan
irradiates more normal tissue to the dose levels.
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Chapter 4

Discussion

This study compared helical tomotherapy to mixed beam (IMRT and electrons) for parotid gland
and nasal cavity tumors. Dosimetric and biological metrics were calculated and used to evaluate the
plans, in addition to a clinical evaluation based on a radiation oncologist‟s review.
The results of this research do not support the hypothesis that HT plans have improved dose
homogeneity with equal or better normal tissue sparing than mixed beam treatments for select superficial
head and neck cancers. Our results showed that HT plan did provide better dose homogeneity than the
mixed beam plans. In all five patients, the DHI of HT was better than that in the mixed beam plans, with
the largest differences observed in patients 3 and 5. However, HT plans did not have equal or better
normal tissue sparing than the mixed beam treatments for all the organs of interest. For example, the
contralateral parotid received a lower mean dose in all patients from the mixed beam plan, which resulted
in a lower NTCP value for salivary flow reduction. For patients 1, 2, 3, and 4, the eyes and the lens
received a lower maximum dose with the mixed beam plan than with the HT plan. However, the HT
delivered a lower maximum dose to the spinal cord and lower volume of high dose to the brain than
mixed beam, as seen in patient 3.
Three specific aims were completed to test the hypothesis. In Aim 1, five patients were selected
that had superficial PTVs (limited to a 5.5 cm depth), among these were 3 parotid tumors and 2 nasal
cavity tumors.
In Aim 2, these patients were planned using both the TomoTherapy Hi-Art (for the HT plans) and
Pinnacle treatment system (for the mixed beam plans). Planning parameters (pitch, jaw width, etc) and
optimization of the HT plan followed typical clinical protocol for head and neck plans. For the mixed
beam plans, seven different ratios of photons to electrons were investigated and optimization procedure
for the mixed beam plans was as follows. For each trial, the electron ratio for the prescribed dose was
delivered by a single electron beam to a point in the PTV. Following the dose computation for the
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electron beam, Pinnacle‟s inverse-planning method was used by the IMRT photons to contribute dose to
deficient volumes in the PTV.
In Aim 3, a clinical, dosimetric, and biological evaluation was made of the plans.
4.1

Outcome of Clinical Comparison
The clinical evaluation consisted of a radiation oncologist review of the plans for clinical

acceptability and to determine how the HT plan compared to the mixed beam plan. After reviewing the
spatial dose distributions and superimposed DVHs of both the HT and mixed beam plans, the radiation
oncologist ranked the HT plan to be superior and marginally superior for parotid patients 1 and 3 and was
indifferent about the HT plan for parotid patient 2 when compared to the mixed beam plans. The
radiation oncologist ranked the HT plan to be indifferent for nasal cavity patient 4 and marginally inferior
for nasal cavity patient 5 when compared to the mixed beam plans.
The basis for his judgment was his clinical experience. Some of the reasons he chose the HT plan
over the mixed beam were 1) Improved PTV uniformity and coverage, 2) the ability of HT plans to spare
specified OARs in close proximity to the PTV, 3) the ability to treat, if desired, separate nodal
involvement, without have to match abutting fields, and 4) the absence of having to use more than one
modality to treat. On the other hand, he had concerns about lens and eye dose in the nasal cavity patients
and preferred to have shielding for the eyes.
4.2

Outcome of Dosimetric Comparison
The dosimetric evaluation consisted of computing the maximum and minimum doses in the PTV,

CI of the PTV, DHI within the PTV and also mean and maximum doses for OARs. The results of the
dosimetric evaluation showed that HT plans had lower DHI values in all plans and in general trended to
have higher CI values than the mixed beam plans. The mean dose to the contralateral parotid was higher
for the HT plans.
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4.3

Outcome of Biological Comparison
The biological evaluation consisted of computing TCP, NTCP, and volumes of normal tissue

irradiated to low dose. The results showed similar TCP values for the HT and mixed beam plans.
Slightly higher NTCP values for the lens and also for distal organs such as the contralateral parotid. For
all but patient 1, the volume of normal tissue irradiated to a dose between 5 Gy and 25 Gy (dose likely to
induce secondary cancers, Schneider et al. 2005) was larger for the HT plans. While secondary cancers
are extremely rare, this may be a concern for younger patients who have longer survival times which may
be at risk of radiation induced cancers. However the rarity of this occurring, as suggested by the clinical
experience of the radiation oncologist reviewing the plans, may not make it a significant factor when
comparing the two plans.
4.4

Connection with Existing Literature
Some of the data from this study are consistent with previous head and neck studies comparing

HT to IMRT. For example, Lee et al. (2008) found that helical tomotherapy treatment plans were
comparable to or slightly better than IMRT plans for treatment of parotid tumors. The comparison of
DHI, NTCP, and TCP for HT and IMRT plan of the three parotid patients in this study was consistent
with the findings of Lee et al. Their average DHI difference between HT and IMRT for the primary PTV
was 0.12 compared to this study‟s average differences of 0.06. NTCP (salivary flow reduction to <25%
at 6 wks) for the contralateral parotid was 2.3% for their study and 1.2% in this study. TCP values varied
slightly more (8%) in Lee et al. study since all patients in that study required multiple PTV targets and
only one patient in this study had multiple PTVs.
However, some of our results differ from previous studies that investigated the feasibility of using
mixed beams to treat head and neck cancers. For example, Cozzi et al., (2001) found that conventional
techniques of mixed photon and electron fields inferior to IMRT treatments in advanced head and neck
cancers. Dose homogeneity was significantly worse for the mixed beam plans than the IMRT plans. 4%
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of the PTV of their mixed beam plans was outside the 90% isodose while less than 2% of their IMRT
plan was. This is inconsistent with this study in that the mixed beam plans had similar PTV coverage and
dose homogeneity (as seen in the DVH section of the results). Theses discrepancies may be explained by
differences in the optimization of the photon component of the mixed beam. Rather than weighting the
two modalities, in this study the IMRT plan was optimized over the electron contribution. Also in this
study, we limited patients to more superficial treatment sites. This benefits the electron beam‟s dose
distribution if it falls off before the edge of the PTV.
4.5

Strength of this Study
Because of the optimization of the IMRT plan over the electron beam dose distribution, we were

able to compare an advanced mixed beam technique to the HT plans. Another strength of this study was
the selection of superficial sites, which made a comparison between mixed beam and IMRT treatments
more interesting. The optimization approach and selected sites makes this study unique relative to the
existing literature.
4.6

Limitations of this Study
In this study we examined two classes of superficial head and neck cancer, three cases in the

parotid gland and two in the nasal cavity, while these sites both met the superficial target criteria; they are
quite different in terms of target geometry and adjacent critical structures. In addition, substantial
variations in target geometry were noted even within the parotid subset (for example, patient 3 contained
three separate PTVs whereas patients 1 and 2 only contained one). As a result, it does not appear that
enough sites similar in geometry were chosen to draw definitive conclusions on whether a statistical
significance existed between HT and mixed beam plan for these subsets of cancers. However, the
variations in treatment sites allowed this work to serve as a preliminary study of the types of superficial
sites that would benefit from combinations of electrons and IMRT. Increasing the sample size in both the
parotid and nasal cavity patients could help confirm the results of this study.
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Another possible limitation could be delivering the mixed beam plans. The IMRT component of
the mixed beam plan was used to fill in the areas of the electron dose distribution that did not meet the
desired prescription for the PTV. In these regions, potential high dose gradients in the mixed beam plan
could introduce hot/cold spots in the presence of slight mismatches in the field alignment. As a result,
because multiple modalities were used in the mixed beam plans, additional precautionary measures may
be required for ensuring safe delivery.
Finally, it should be noted that the parotid patients were all planned with a bolus to give a high
skin dose, especially at surgical scars and to compensate for missing tissue on the surface. In this study
the bolus was of uniform thickness. The bolus however could have been a variable thickness bolus
compensator in order to improve the dose distribution from the electron beam component. Since the
IMRT component fills in the difference between the electron contribution and prescription, the advantage
of a variable thickness bolus could reduce large dose gradients utilized in the IMRT plan.
4.7

Future Work
The findings in this study suggest that mixed beam treatments could be used as an effective

alternative for reducing the dose to distal critical organs to values near electron beam only while at the
same time restoring the TCP to levels near HT and IMRT. The next step is to study how a variable
thickness bolus compensator affects the dose distributions. These studies should include the combination
of bolus electron conformal therapy with IMRT to improve the DHI values from the mixed beam plans
seen in this study. In addition, based on the preliminary results of the different ratios of photons to
electrons used in this study, future studies should utilized the heavier electron weighted (1:3 and 1:4
ratios) mixed beam plans and investigate a larger sample of similar patients in order to confirm
statistically significance of difference between HT and mixed beam plans.
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Chapter 5

Conclusions

The preliminary investigation of HT and mixed beam plans for superficial head and neck cancers
showed that HT plans can deliver dose distributions with increased dose conformity and improved dose
homogeneity index for three parotid gland and two nasal cavity tumors than mixed beam plans. However,
larger volumes of contralateral critical structures (the untreated parotid gland) and normal tissue received
low dose with HT in the parotid plans. In the nasal cavity plans, larger volumes of adjacent critical
structures (the lens) and normal tissue received low dose with HT. For patients with a single shallow
uniform PTV, mixed beam plans yield more favorable PTV and OAR results.
In conclusion, HT plans delivered a more uniform dose distribution to the PTV in all five
patients. Based on TCP values and radiation oncologist evaluations, mixed beam plans were also able to
deliver clinically acceptable PTV coverage while sparing specified normal tissue (e.g. contralateral
parotid gland). However, more studies should be done to address slight variability in the results among
the treatment sites and geometries of the PTV.
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Appendix A: Radiation Oncologist Evaluation of Treatment Plans
Radiation Oncologist Evaluation of Treatment Plans
Date:
Patient ID: Patient 1,
a.) Evaluate the clinical acceptability of plans. Please check one category that closely
describes your observation for each plan.
Marginally
Clinical acceptability
Photon plans
TomoTherapy
1:0 IMRT
IMRT with electron plans

Acceptable

acceptable

Marginally
Indifferent

unacceptable

Unacceptable

X
X

(photon:electron ratio)
2:1 IMRT w/electron
(ratio in favor of photons)
1:1 IMRT w/ electron
1:2 IMRT w/electron
1:3 IMRT w/electron
1:4 IMRT w/electron
0:1 electrons

Plan to plan
comparison

X
X
X
X
X
X

b.) Compare the TomoTherapy plan with the best IMRT with electron plan.
i. How does the TomoTherapy plan compare with the best IMRT
with electron plan? Please check one category that best describes
your observation.
Marginally
Superior Marginally superior Indifferent inferior
Inferior

TomoTherapy vs
IMRT w/electrons

X
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Radiation Oncologist Evaluation of Treatment Plans
Date:
Patient ID: Patient 2,
a.) Evaluate the clinical acceptability of plans. Please check one category that closely
describes your observation for each plan.
Marginally
Clinical acceptability

Acceptable

Photon plans
TomoTherapy
1:0 IMRT
IMRT with electron plans

X
X

acceptable

Marginally
Indifferent

Unacceptable

Unacceptable

(photon:electron ratio)
2:1 IMRT w/electron
(ratio in favor of photons)
1:1 IMRT w/ electron
1:2 IMRT w/electron
1:3 IMRT w/electron
1:4 IMRT w/electron
0:1 electrons

Plan to plan
comparison

X
X
X
X
X
X

b.) Compare the TomoTherapy plan with the best IMRT with electron plan.
i. How does the TomoTherapy plan compare with the best IMRT
with electron plan? Please check one category that best describes
your observation.
Marginally
Superior Marginally superior Indifferent inferior
Inferior

TomoTherapy vs
IMRT w/electrons

X
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Radiation Oncologist Evaluation of Treatment Plans
Date:
Patient ID: Patient 3,
a.) Evaluate the clinical acceptability of plans. Please check one category that closely
describes your observation for each plan.
Marginally
Clinical acceptability
Photon plans
TomoTherapy
1:0 IMRT
IMRT with electron plans

Acceptable

acceptable

Marginally
Indifferent

Unacceptable

Unacceptable

X
X

(photon:electron ratio)
2:1 IMRT w/electron
(ratio in favor of photons)
1:1 IMRT w/ electron
1:2 IMRT w/electron
1:3 IMRT w/electron
1:4 IMRT w/electron
0:1 electrons

Plan to plan
comparison

X
X
X
X
X

b.) Compare the TomoTherapy plan with the best IMRT with electron plan.
i. How does the TomoTherapy plan compare with the best IMRT
with electron plan? Please check one category that best describes
your observation.
Marginally
Superior Marginally superior Indifferent inferior
Inferior

TomoTherapy vs
IMRT w/electrons

X
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Radiation Oncologist Evaluation of Treatment Plans
Date:
Patient ID: Patient 4,
a.) Evaluate the clinical acceptability of plans. Please check one category that closely
describes your observation for each plan.
Marginally
Clinical acceptability
Photon plans
TomoTherapy
1:0 IMRT
IMRT with electron plans

Acceptable

acceptable

Marginally
Indifferent

Unacceptable

Unacceptable

X
X

(photon:electron ratio)
2:1 IMRT w/electron
(ratio in favor of photons)
1:1 IMRT w/ electron
1:2 IMRT w/electron
1:3 IMRT w/electron
1:4 IMRT w/electron
0:1 electrons

Plan to plan
comparison

X
X
X
X
X
X

b.) Compare the TomoTherapy plan with the best IMRT with electron plan.
i. How does the TomoTherapy plan compare with the best IMRT
with electron plan? Please check one category that best describes
your observation.
Marginally
Superior Marginally superior Indifferent inferior
Inferior

TomoTherapy vs
IMRT w/electrons

X
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Radiation Oncologist Evaluation of Treatment Plans
Date:
Patient ID: Patient 5,
a.) Evaluate the clinical acceptability of plans. Please check one category that closely
describes your observation for each plan.
Marginally
Clinical acceptability

Acceptable

Photon plans
TomoTherapy
1:0 IMRT
IMRT with electron plans

acceptable

Marginally
Indifferent

unacceptable

Unacceptable

X
X

(photon:electron ratio)
2:1 IMRT w/electron
(ratio in favor of photons)
1:1 IMRT w/ electron
1:2 IMRT w/electron
1:3 IMRT w/electron
1:4 IMRT w/electron
0:1 electrons

Plan to plan
comparison

X
X
X
X
X
X

b.) Compare the TomoTherapy plan with the best IMRT with electron plan.
i. How does the TomoTherapy plan compare with the best IMRT
with electron plan? Please check one category that best describes
your observation.
Marginally
Superior Marginally superior Indifferent inferior
Inferior

TomoTherapy vs
IMRT w/electrons

X
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Appendix B: Isodose Distributions
Patient 1

Figure 39 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 1 for 0:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 40 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 1 for 1:4 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 41 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 1 for 1:3 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 42 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 1 for 1:2 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 43 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 1 for 1:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 44 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 1 for 2:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 45 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 1 for the IMRT plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 46 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 1 for the TomoTherapy plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as red colorwash
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Patient 2

Figure 47 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 2 for 0:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 48 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 2 for 1:4 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 49 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 2 for 1:3 ratio plan. The white crosshair in dicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 50 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 2 for 1:2 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 51 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 2 for 1:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 52 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 2 for 2:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 53 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 2 for the IMRT plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 54 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 2 for the TomoTherapy plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as red colorwash
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Patient 3

Figure 55 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 3 for 1:4 ratio plan. The white crosshair indicates the position of
the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal; PTV54,
yellow
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Figure 56 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 3 for 1:3 ratio plan. The white crosshair indicates the position of
the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal; PTV54,
yellow
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Figure 57 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 3 for 1:2 ratio plan. The white crosshair indicates the position of
the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal; PTV54,
yellow
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Figure 58 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 3 for 1:1 ratio plan. The white crosshair indicates the position of
the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal; PTV54,
yellow
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Figure 59 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 3 for 2:1 ratio plan. The white crosshair indicates the position of
the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal; PTV54,
yellow
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Figure 60 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 3 for the IMRT plan. The white crosshair indicates the position of
the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal; PTV54,
yellow
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Figure 61 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 3 for the TomoTherapy ratio plan. The white crosshair indicates the
position of the planes shown. PTVs are shown in colorwash. Primary PTV, purple; PTV60, teal;
PTV54, yellow
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Patient 4

Figure 62 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 4 for 0:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 63 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 4 for 1:4 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 64 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 4 for 1:3 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 65 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 4 for 1:2 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 66 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 4 for 1:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 67 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 4 for 2:1 ratio plan. The white crosshair indicates the positi on of
the planes shown. The PTV is displayed as red colorwash
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Figure 68 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 4 for the IMRT plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 69 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 4 for the TomoTherapy ratio plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as red colorwash
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Patient 5

Figure 70 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 5 for 0:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash

136

Figure 71 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 5 for 1:4 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 72 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 5 for 1:3 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 73 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 5 for 1:2 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 74 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 5 for 1:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 75 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 5 for 2:1 ratio plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 76 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 5 for the IMRT plan. The white crosshair indicates the position of
the planes shown. The PTV is displayed as red colorwash
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Figure 77 Isodose dose distributions in transverse (a), sagittal (b), and coronal planes (c) through
the center of the PTV in patient 5 for the TomoTherapy ratio plan. The white crosshair indicates the
position of the planes shown. The PTV is displayed as red colorwash
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